

The Guidelines project was entirely
supported by the European Glaucoma
Society Foundation

CHAPTER 2

Classification and Terminology



Copyright © 2014 European Glaucoma Society

No parts of this text, illustrations, tables or flowcharts can be reproduced, copied, translated or stored by any means including magnetic, electronic or multimedia formats without written permission of the European Glaucoma Society.

The Guidelines project was entirely supported by the European Glaucoma Society Foundation

2.1 - PRIMARY CONGENITAL FORMS/CHILDHOOD GLAUCOMAS

Primary congenital glaucoma is a rare disease but has a major impact on the child's development and quality of life over his/her whole life span. Early diagnosis and appropriate therapy can make a huge difference in the visual outcome and can prevent lifelong disability. Surgical treatment is always necessary^{1, 2} [I,C].

2.1.1 Primary congenital glaucoma (PCG): from birth to >2 years of life

- (1) Neonatal or newborn onset (0-1 month)
- (2) Infantile onset (>1 until 24 months)
- (3) Late onset or late recognized (>2 years)
- (4) Spontaneously non-progressing cases with normal IOP but typical signs of PCG may be classified as PCG

Etiology:

Angle dysgenesis is caused by incomplete development of the trabecular meshwork before and/or after birth. Strong monogenetic influence. Heredity shows recessive inheritance with variable penetrance in most cases or is sporadic. Specific chromosomal abnormalities have been identified at chromosomes 1p36 and 2q21².

Pathogenic mechanism:

Decreased aqueous outflow causes significant elevation of IOP. Isolated trabeculodysgenesis is the most common form of primary congenital glaucoma.

Epidemiology:

Congenital glaucoma occurs in about 1 in 12-18,000 births among Caucasians. Incidence can be 5 to 10 times higher if consanguinity of parents is present. Severe visual disability is common. PCG is more common in males (65%), and is bilateral in 70% of patients.

Symptoms:

Crying unhappy child during first weeks or year of life.
Not always symptomatic.

Signs:

Photophobia, tearing, blepharospasm, and eye rubbing are typical early signs. Eyes are larger compared to age, with corneal diameter usually >10.5 mm at birth and >12 mm in the first year of life. Axial length is increased, >20 mm at birth or >22 mm after 1 year. Corneal oedema is frequent; epithelial and stromal oedema can be associated with ruptures of Descemet's Membrane, or Haab's striae, not to be confused with forceps delivery trauma. IOP can sometimes be measured in the awaked child with hand-held tonometers. Under general anesthesia the level of IOP is often artificially lowered by sedation and anesthetic medications: IOP values alone are insufficient to confirm the diagnosis unless IOP is extremely elevated and confirmed by corneal signs. Severe cases show

Classification and Terminology

extremely extended globe when the diagnosis is delayed, described as “buphthalmos” (Ox eye). A useful approach is to compare the width of the palpebral apertures. The optic nerve head shows pressure distension or uniform cup enlargement in newborns; cupping is a typical sign for later stages (CDR >0.3). Optic disc signs may be reversible with the normalization of IOP. Gonioscopy shows anterior insertion of the iris, forming a scalloped line with persistent uveal tissue and poorly differentiated structures and/or trabeculodysgenesis often described as Barkan’s “membrane”.

Treatment:

Initial surgery is indicated in nearly all cases with primary congenital glaucoma²⁻⁶ [I,D]. Classical initial surgery is goniotomy or trabeculotomy^{1, 6-8}. 360° trabeculotomy using a catheter to open the whole circumference of Schlemm’s canal has been described with favourable results⁹⁻¹¹. Filtration surgery may be indicated if these are unsuccessful [I,D]. Repeat surgery is relatively frequent. Medical treatment is usually neither effective nor practicable in the long term. Medications, including oral CALs can be used while decision is made on a surgical approach and for eyes where surgery fails to achieve IOP control.² Cycloablation is an intermediate or add-on procedure when primary trabecular surgery has failed. Severe cases and secondary childhood glaucomas, particularly aphakic childhood glaucoma, sometimes need long-tube drainage device surgery. Cases with later manifestation usually do not have enlargement of the globe and may have a more favourable outcome with surgery.

2.1.2 Late-onset childhood open-angle glaucoma/Early Juvenile (onset >2 to puberty)

Etiology and pathophysiology:

as in PCG, except :

- no ocular enlargement
- no congenital ocular anomalies or syndromes
- asymptomatic until field loss advanced

Signs:

open angle, elevated IOP, optic nerve and visual field damage depending on the stage of disease

Treatment:

See above 2.1.1.1

The treatment of pediatric glaucoma cases is particularly challenging due to the nature of the disease and to the intrinsic difficulties in operating them and in examining patients of this age. Treatment is to be adapted to the primary anomaly, and the mechanism of IOP elevation [I,D]. Whenever possible these cases should be referred to tertiary care centers.

Classification and Terminology

2.1.3 Secondary Childhood Glaucoma

A variety of pathogenic mechanisms are possible. A complete list and extensive discussion are outside the scope of the guidelines.

2.1.3.1 Glaucoma associated with non-acquired ocular anomalies

- Axenfeld Rieger anomaly (Syndrome if systemic associations)
- Peters anomaly (Syndrome if systemic associations)
- Ectropion uveae
- Congenital iris hypoplasia
- Aniridia
- Persistent fetal vasculature/PFV (if glaucoma present before cataract surgery)
- Oculodermal melanocytosis (Nevus of Ota)
- Posterior polymorphous dystrophy
- Microphthalmos
- Microcornea
- Ectopia lentis

2.1.3.2 Glaucoma Associated with Non-acquired Systemic Disease or Syndrome

- Chromosomal disorders such as Trisomy 21 (Down syndrome)
- Connective tissue disorders
 - Marfan syndrome
 - Weill-Marchesani syndrome
 - Stickler syndrome
- Metabolic disorders
 - Homocysteinuria
 - Lowe syndrome
 - Mucopolysaccharidoses
- Phacomatoses
 - Neurofibromatosis (NF-1, NF-2)
 - Sturge-Weber syndrome
 - Klippel-Trenaunay-Weber syndrome
 - Rubinstein-Taybi
 - Congenital rubella

2.1.3.3 Glaucoma Associated with Acquired Condition

- Uveitis
- Trauma (hyphema, angle recession, ectopialentis)
- Steroid induced
- Tumors (benign/malignant, ocular/orbital)
- Retinopathy of Prematurity

2.1.3.4 Glaucoma Following Childhood Cataract Surgery

Secondary glaucoma is a frequent serious complication after cataract surgery in early infancy. The incidence may increase up to 50% if cataract surgery is performed before the 9th month of life^{12, 13}. This secondary glaucoma is difficult to treat and often needs long-tube drainage device surgery for long-term OP control.

2.1.3.5 Treatment of secondary childhood glaucoma [I,D]

The management of these cases is particularly challenging. Medical treatment is usually not effective nor practicable in long term. Medications, including oral CAIs can be used while decision is made on a surgical approach and in case of failed surgery while awaiting for further options.

Primary surgery: early goniotomy or trabeculotomy or filtration surgery may be indicated if these are unsuccessful. Repeat surgery is relatively frequent. Treatment to be adapted to the primary anomaly, the mechanism of IOP elevation and the quality of life of the patient. These cases require highly specialized care.

Classification and Terminology

2.2 - PRIMARY OPEN-ANGLE GLAUCOMAS

The open-angle glaucomas are chronic, progressive optic neuropathies, that have in common characteristic morphological changes at the optic nerve head and retinal nerve fibre layer in the absence of other ocular disease or congenital anomalies. Progressive retinal ganglion cells death and visual field loss are associated with these changes.

2.2.1 Epidemiology

Glaucoma is the second leading cause of blindness both in Europe and worldwide. It is the most frequent cause of irreversible blindness. POAG is unusual under the age of 50 yrs. Its prevalence increases with age¹⁴⁻²⁵. However, the reported percentage largely depends on definition.

2.2.2 Risk factors for open-angle glaucoma

As most population studies did not differentiate between POAG and secondary open angle glaucomas such as pseudoexfoliation (PEX) glaucoma, the following statements apply to both varieties, here are labelled OAG.

o Risk assessment

Consideration of risk factors is important: it helps to identify individuals who can be targeted for early detection and to guide management decisions about the initiation and escalation of treatment in established glaucoma patients.

o Terminology

Risk Factors: risk factors for open-angle glaucoma (OAG) are those statistically associated with the development of OAG or conversion from ocular hypertension to glaucoma²⁶.

Prognostic Factors: prognostic factors for OAG are statistically associated with the progression of established OAG. Neither risk factors nor prognostic factors establish causation. Sometimes the terms risk factors and prognostic factors are used interchangeably.

Predictive Factors: the term predictive factors should be used for factors which are associated with increased risk for glaucoma and which are part of the definition of OAG, such as optic disc parameters and visual field indices.

2.2.2.1 Risk factors for the development of OAG (See FC V)

Initial evidence on potential risk factors for OAG has been provided by cross-sectional population-based studies. Firm conclusions on risk factors for the development of OAG can only be drawn by longitudinal population-based cohort studies²⁷⁻³⁰.

- a) **Age** Cross-sectional population-based studies have consistently reported that the prevalence of OAG increases dramatically with age^{14-17,19-25,31}. Longitudinal population-based studies have confirmed that older age is an important risk factor for OAG^{27,30}. Two studies reported a 6% and 4% increased risk per year of age at baseline of developing OAG.
- b) **Intraocular pressure (IOP)** Higher IOP has been consistently associated with the prevalence^{14-17,19-25,31} and incidence of OAG^{27,28,30,32}. According to longitudinal data, the risk of developing OAG increases by 11-12% in Caucasians^{27,28}, 10% in people of African origin³² and 18% in Latinos³⁰ for each 1 mmHg increase in IOP. To date, IOP is the only modifiable risk factor for OAG.
- c) **Race/ethnicity** The prevalence of glaucoma is several times higher in African-Americans and Afro-Caribbeans than in Caucasians^{18,33,34}. In Latinos, it has been shown that the prevalence²⁰⁻²³ and incidence³⁵ of OAG is higher than in Caucasians, but lower than in Afro-Caribbeans.
- d) **Family history of glaucoma** Two studies studying different ethnic groups found that the risk of having OAG was 9.2-fold and 4 fold higher, respectively for individuals having a first-degree relative with confirmed OAG, compared with those who did not^{36, 37}. Also, self-reported family history of glaucoma has been associated with increased risk of developing OAG^{27,28}.
- e) **Pseudoexfoliation** Population-based studies which specifically assessed pseudoexfoliation and pseudoexfoliative glaucoma have consistently reported that pseudoexfoliation is associated with increased prevalence of OAG^{19,24,38-47}. Based on longitudinal data, the presence of pseudoexfoliation is associated with an 11.2-fold increased risk of developing OAG²⁷.
- f) **Central corneal thickness (CCT)** In two population based studies, there was a 41% and 30% increased risk of developing OAG per 40 µm thinner CCT^{29,48}.
- g) **Myopia** Several cross-sectional population-based studies identified moderate to high myopia (greater than -3 diopters) as a factor associated with increased OAG

Classification and Terminology

prevalence^{47,49-55}. A Dutch study showed that subjects with high myopia (greater than -4 D) had a 2.3-fold increased risk for developing OAG²⁸. Latinos in California had a risk of OAG increased by 48% with each 1 mm increase in axial length³⁰.

h) **Ocular perfusion pressure**

The association of low ocular perfusion pressure with increased OAG prevalence has been a consistent finding in population-based studies^{50,31,56-61}. Recent evidence suggests that this association may depend on whether subjects are treated for systemic hypertension or not^{29,56,58,61-66}. A phenotype characterized by vascular dysregulation has been described⁶⁴. The Barbados Eye Study confirmed that low ocular perfusion pressure increases the risk for the development of OAG²⁹. Because of our limited understanding of this complex variable and of its interaction with potential risk factors for glaucoma, the exact place of ocular perfusion pressure in glaucoma management remains unclear⁶⁷⁻⁶⁹.

i) **Other factors**

There have been reports on other factors that may be associated with increased risk for OAG, such as diabetes, systemic blood pressure, migraine, Raynaud syndrome and obstructive sleep apnoea. However, data from the literature are inconsistent.

j) **Risk factors by type of OAG**

In general, population-based studies analyses have not differentiated between types of OAG. A recent analysis which considered POAG and PEX glaucoma revealed that IOP was the only factor associated with both of them; vascular systemic diseases and their treatment were associated only with POAG⁴⁷. This may suggest differences in pathogenesis between these two common types of OAG.

2.2.2.2 Risk factors and predictive factors for the conversion of ocular hypertension to POAG

The Ocular Hypertension Treatment Study (OHTS), and the European Glaucoma Prevention Study (EGPS)⁷⁰ are two randomized controlled trials (RCTs) which evaluated the effect of IOP-lowering treatment on the conversion of ocular hypertension to POAG. The following risk factors and predictive factors were consistently reported in both the OHTS and the EGPS:

- ∞ Age (risk increased by 26% per decade)
- ∞ IOP (risk increased by 9% per 1 mmHg)
- ∞ Vertical and horizontal cup-to-disc ratio (risk increased by 19% per 0.1 larger)
- ∞ Pattern standard deviation (PSD) in the visual field (risk increased by 13% per 0.2 dB greater)
- ∞ CCT (2.04 fold increased risk per 40 µm thinner)

Based on the pooled OHTS–EGPS predictive model, a quantitative calculator was developed to estimate the 5-year risk for the conversion of ocular hypertension to POAG⁷¹. This tool is available to the clinician and may help to discuss frequency of visits and possible treatment.

However, limitations should also be considered. Because the calculator was based on the OHTS and EGPS data sets, results may not apply to individuals < 40 years old, individuals who have untreated IOPs < 22 mmHg or who are not of Caucasian or of African origin. Also, the calculator does not take into account other factors associated with increased risk for glaucoma, such as family history of glaucoma and pseudoexfoliation. In addition, life expectancy issues should be addressed.

2.2.2.3 Prognostic factors for progression of OAG

Factors associated with the progression of established OAG have been identified by large RCTs: Early Manifest Glaucoma Trial (EMGT)⁷², Advanced Glaucoma Intervention Study (AGIS)⁷³, Collaborative Initial Glaucoma Treatment Study (CIGTS)⁷⁴, Collaborative Normal Tension Glaucoma Study (CNTGS)⁷⁵.

a) **Age**

Older age is significantly associated with increased risk for the progression of OAG. In the EMGT, after a mean follow-up of 8 years, patients \geq 68 years old had a 51% increased risk of progression compared to those who were younger⁷². In the AGIS the risk of progression increased by 30% with every 5 years increase in age⁷³; in CIGTS the risk increased by 35% for every decade⁷⁴. Also, in the untreated arm of the EMGT, progression was considerably faster in older than in younger patients⁷⁵.

b) **IOP**

Most of the above RCTs suggest a positive effect of IOP reduction on the onset or progression of glaucomatous damage. In the EMGT the risk of progression decreased by about 10% with each mmHg of IOP reduction from baseline to the first follow-up visit⁷⁷. Conversely, the role of long term IOP fluctuation in glaucoma progression is still debated^{78–80}. Also, the role of diurnal IOP fluctuation in glaucoma progression needs to be investigated more thoroughly in RCTs.

c) **Pseudoexfoliation**

In the EMGT, the risk of progression increased by a 2.12-fold in those with pseudoexfoliation compared with those without pseudoexfoliation⁷². In addition, in the untreated arm of the EMGT, progression was considerably faster in eyes with pseudoexfoliation, despite similar baseline IOP values between the pseudoexfoliative and non pseudoexfoliative eyes⁷⁶. Pseudoexfoliation has not been evaluated in the AGIS, CIGTS and CNTGS.

d) **CCT**

In the EMGT, thinner CCT was a significant but weak prognostic factor for OAG


Classification and Terminology

and this association was observed only in patients with higher baseline IOP⁷². The role of CCT in glaucoma progression has not been evaluated in the AGIS, CIGTS and CNTGS.

e) Disc haemorrhages

In the CNTGS the presence of optic disc haemorrhages was significantly associated with glaucoma progression⁸⁰. Also, in the EMGT patients with disc haemorrhages had significantly shorter time to progression⁸¹. A systematic review (January 1950-January 2013) evaluating risk factors for glaucoma among routine diagnostic examination reported disc haemorrhage (LR, 12; 95% CI, 2.9-48) being highly suggestive of glaucoma, but the absence of a haemorrhage was nondiagnostic (LR, 0.94; 95% CI, 0.83-0.98)⁸².

FC V - Assessment and Follow-up



Follow-up intervals are just recommendations

POAG = primary open-angle glaucoma
 OHT = ocular hypertension
 IOP = intraocular pressure
 CCT = central corneal thickness
 Rx = therapy

RULE OUT PRIMARY ANGLE-CLOSURE

2.2.3 Primary Open-Angle Glaucoma

Definition:

Primary open-angle glaucoma (POAG) is a chronic progressive optic neuropathy with characteristic morphological changes at the optic nerve head and retinal nerve fibre layer in the absence of other ocular disease or congenital anomalies. Progressive retinal ganglion cell death and visual field loss are associated with these changes.

Etiology:

The etiology of primary open angle glaucoma remains unclear. Multiple genetic factors and the influence of co-morbidities are likely to play a role.

Pathophysiology:

The current concept of how damage is elicited includes deformation of the lamina cribrosa caused by IOP levels that are not tolerated by the individual eye. This is thought to result in axonal damage with consequent apoptotic death of the retinal ganglion cells. A substantial proportion of patients develop POAG at IOPs within the normal range. Any increase in IOP is caused by elevated outflow resistance in the trabecular meshwork outflow pathways.

Treatment:

POAG is treated by reducing intraocular pressure using medication, laser or incisional surgery (See Ch 3). So far, there is no evidence for other suggested treatment modalities, e.g. neuroprotection or modifying blood flow.

2.2.3.1 Primary Open-Angle Glaucoma / High Pressure Glaucoma (POAG/HPG)

The relative risk for POAG rises continuously with the level of the intra-ocular pressure (IOP), and there is no evidence of a threshold IOP for the onset of the condition. It is presumed that risk factors other than IOP have a relatively greater importance if there is glaucomatous optic neuropathy at the lower (statistically 'normal') pressure levels. POAG has been arbitrarily subdivided into High Pressure and Normal-Pressure disease to reflect this, even though they may represent a spectrum of optic neuropathies variably sensitive to the IOP. See Ch. introduction.

Etiology:

Unknown

Pathomechanism:

Unknown.

TIGR and Myoc mutations may be associated^{83, 84}.

Features:

- ∞ Onset: from the young adult age onwards
- ∞ Signs and symptoms:
 - Asymptomatic until field loss advanced
 - Elevated IOP without treatment (diurnal tension curve)

Classification and Terminology

- ∞ Optic nerve head: acquired characteristic glaucomatous damage and/or retinal nerve fiber layer changes (diffuse or localized defects) (See Ch. 1)
- ∞ Visual field: usually detectable glaucomatous defects corresponding to the optic disc damage may be present
- ∞ Gonioscopy: open anterior chamber angle (not occludable, no goniodysgenesis). (See Ch. 1).

Treatment:

Refer also to Introduction II and Ch. 3

A target pressure is to be identified for each case (See also Ch. 3.2 and FC IX-X) [I,D].

- a)** Medical treatment (See FC XI-XIII)
 - 1. Mono therapy
 - 2. Combination therapy as needed in selected patients
- b)** Laser trabeculoplasty (LTP)
- c)** Filtration Surgery with / without antimetabolites
- d)** Adjunctive medical therapy when needed
- e)** Insertion of aqueous long- tube drainage implants
- f)** Cyclodestructive procedures

Choice of primary therapeutic modality needs to be made on an individual patient basis [I,D].

Laser trabeculoplasty can be considered as primary treatment and as an alternative to additional medications [I,A].

2.2.3.2 Primary Open-Angle Glaucoma / Normal–Pressure Glaucoma (POAG/NPG)

Etiology:

Unknown

Pathomechanism:

Unknown.

Optineurin mutation has been found in families with NPG

Features:

- ∞ Onset: from the 35th year onwards
- ∞ Signs and symptoms:
 - Normal IOP without treatment (diurnal curve or 24-hour phasing). Asymptomatic until field loss advanced
 - Optic nerve head damage typical of glaucoma
 - Disc haemorrhages
- ∞ Visual field defects typical of glaucoma; e.g. paracentral defects
- ∞ Gonioscopy: open anterior chamber angle (exclude intermittent angle-closure; See Ch. 2)
- ∞ No history or signs of other eye disease or steroid use.
- ∞ Consider central corneal thickness if findings do not match; CCT may be thinner than average (See Ch. 1.1).

Treatment:

Refer also to Chapter Introduction II, Ch. 3 and FC VI
There are few prospective clinical trials indicating clearly the advantages of treatment [I,A].
Target pressure: in most cases a peak IOP = 8 mm - 15 mm Hg on diurnal curve or a 30% IOP reduction from baseline (See Ch. 3.2) [I,D]

- a) Medical therapy:
 - I. Any drug singly or in combination which is effective and tolerated, whose IOP lowering effect is sufficient to reach a maintain the target IOP [I,D]
 - II. Avoid medications with potential vasoconstrictive effects or with systemic hypotensive effects [II,D]
 - III. Oral calcium channel blockers are being investigated in selected patients by some investigators.
- b) Laser trabeculoplasty [I,D]
- c) Glaucoma Surgery:
 - In cases of progressive glaucomatous damage, in spite of maximal medical therapy or laser trabeculoplasty, or failure to reach target pressure [I,D]. Intensive postoperative care with bleb manipulation may be needed to maintain low IOPs [I,D]

Follow-up intervals, depending on the stage of disease and on the rate of progression, with examination of [II,D]:

- ⌘ Optic disc
- ⌘ Visual field
- ⌘ IOP
- ⌘ ONH and RNFL documentation

2.2.4 Primary Juvenile Glaucoma

- ∞ Etiology: Unknown
- ∞ Pathomechanism: Decreased aqueous outflow
- ∞ Features:
 - Onset: beyond infancy, usually after puberty or early adulthood. Heredity: if familiar frequently dominant trait. Genes associated with primary juvenile glaucoma have been identified as MYOC and CYP1B1
 - Signs and symptoms:
 - ⌘ No enlargement of the globe
 - ⌘ Asymptomatic until field loss is advanced
 - ⌘ Elevated IOP without treatment (diurnal tension curve)
 - ⌘ Optic nerve head and RNFL: Diffuse damage typical, but any type of glaucomatous damage
 - ⌘ Visual field: glaucomatous defects
 - ⌘ Gonioscopy: wide open anterior chamber angle, often poorly differentiated
 - ⌘ No congenital or developmental anomalies

Classification and Terminology

Treatment [I,D] (See FC VI):

- a. Medical therapy: any effective and well tolerated topical regimen. Pilocarpine causes fluctuating myopic shift, visual symptoms and headache particularly in the young and should be avoided.
- b. Surgery: early surgery often required filtering procedure or trabeculectomy; consider antimetabolites.
- c. Laser trabeculectomy: not recommended due to poor and short-lived IOP lowering effect.

2.2.5 Primary Open-Angle Glaucoma Suspect (POAG)

Etiology:

Unknown

Pathomechanism:

Unknown

Features:

- ∞ Visual field and/or optic disc and/or nerve fiber layer normal or suspicious, with at least one being suspicious
- ∞ IOP can be normal or increased

Treatment [I,D] (See FC VI):

Risks and benefits of treatment need to be weighed against the risk of the development of glaucomatous disc damage. The risk of developing glaucoma increases with the number and strength of risk factors.

The indication for any form of therapy is relative

- a) Medical therapy: any topical agent alone or in combination as long as well tolerated and effective
- b) Avoid adjunctive medical treatment unless strictly needed
- c) Laser trabeculectomy: not usually indicated
- d) Filtering operation: not indicated
- e) Follow-up [I,D] at intervals of 6-12 months initially, to be increased if all parameters remain normal with examination of:
 - I. Optic disc
 - II. Visual field
 - III. IOP
 - IV. ONH RNFL documentation initially and every 2-3 years

2.2.6 Ocular Hypertension (OH)


Etiology:
Unknown

Pathomechanism:
Unknown

Features:

- ∞ Signs and symptoms:
 - IOP > 21 mm Hg without treatment
 - Visual field: normal
 - Optic disc and retinal nerve fibre layer: normal
 - Gonioscopy: open anterior chamber angle (exclude intermittent angle-closure. See Ch 2.4.2.2)
 - No history or signs of other eye disease or steroid use.
- ∞ Other risk factors: none

FC VI - Treatment Options



If the above procedures not successful or feasible, consider repeat filtration surgery with anti-metabolites or long-tube drainage implant/cyclodestructive procedure

(*) Up to 2-3 different drugs. Do not add a drug to a non-effective one; consider switching

POAG = primary open-angle glaucoma

XFG = exfoliative/pseudoexfoliative glaucoma

PDG = pigment dispersion glaucoma

Classification and Terminology

Treatment:

Although in the past it has been used as a diagnosis, Ocular Hypertension should be used to indicate that the IOP is consistently outside 2 or 3 standard deviations above the mean. Consider corneal thickness (See Introduction II and Ch. 1.1; FC II and IV). A modest increase in IOP is not sufficient reason for treatment, but consider it in patients with repeated IOPs in the high twenties, even without risk factors. For treatment modality See Ch. 4.2.3-a (See also Ch. 2.2.3. and flow-charts).

- ∞ If left untreated (See Ch. Introduction II)
 - up to 9.5% develop glaucoma over 5 year of follow-up
 - the risk of developing glaucoma increases with increasing IOP
 - prophylactic IOP-lowering therapy to be discussed with individual patients considering the presence of risk factors
- Follow-up [II,D] at intervals of 12-24 months initially, to be increased if all parameters remain negative, with examination of:
 - ⚡ Optic disc
 - ⚡ Visual field
 - ⚡ IOP
 - ⚡ ONH and RNFL photographs initially and every 2-3 years

Patients for the ocular hypertension treatment study (Ch. Introduction II) were selected excluding myopes, labile diabetics, poor compliance. In most of Europe black Africans are a minority.

Assess each patient individually when deciding whether or not to treat [I,D].

2.3 - SECONDARY GLAUCOMAS

Secondary glaucomas are a heterogeneous group of conditions, in which elevated IOP is the leading pathological factor causing glaucomatous optic neuropathy. Most forms of secondary glaucoma like uveitic or traumatic glaucoma have complex pathomechanisms including both an open or closed angle.

2.3.1 Secondary Open-Angle Glaucoma

2.3.1.1 Secondary Open-Angle Glaucomas Caused By Ocular Disease

2.3.1.1.1 Exfoliative (pseudoexfoliative) glaucoma

Features:

- ∞ Onset: usually older than 60 years
- ∞ Asymptomatic until visual field loss advanced
- ∞ One or both eyes affected, often bilateral and asymmetrical

Etiology and pathogenic mechanisms.

Exfoliative glaucoma (XFG) develops from exfoliation (pseudoexfoliation) syndrome (XFS), in which an abnormal fibrillo-granular protein (exfoliation material) is produced in the eye and the body. Development of XFS is strongly associated with certain variants of the LOXL1 gene, but the onset of glaucoma may depend on other environmental and/or genetic factors. In the eye exfoliation material accumulates in a characteristic pattern on the anterior lens capsule, pupillary margin, trabecular meshwork and the zonules^{85, 86}. Pigment granules from the posterior layer of the iris are liberated and together with the exfoliation material play an important role in the development of decreased aqueous humour outflow and elevation of IOP, which may lead to the development of glaucoma. Clinically both XFS and XFG may appear in only one eye, but they may develop gradually in the fellow eye in many cases. To identify exfoliation material pupil dilation is recommended. Typically XFG develops after 60 years of age, the IOP is considerably higher than that in POAG, and the diurnal IOP fluctuation is high. As a consequence, in the involved eye(s) optic nerve head damage and visual field deterioration are frequently severe already at the time of the first visit. At a population level, this may partially be counterbalanced by the fact that in certain countries XFG is significantly less undiagnosed than POAG⁸⁷. In XFG the risk for progression is particularly high even when the eye is under IOP lowering treatment⁷⁶. XFS and XFG are associated with poor pupil dilation and other ocular alterations like dense nuclear cataract and zonular damage which make cataract surgery more difficult and increase the risk for surgical complications⁸⁶. Due to zonular damage lens dislocation and resulting secondary angle closure may occur.

Classification and Terminology

Epidemiology:

XFG is the most common type of secondary open angle glaucomas, its prevalence varies considerably across populations^{24, 86}. According to population-based data, XFG develops in approximately 15% to 26% of eyes with XFS (depending on the definition of glaucomatous damage) over a 5 year period²⁷. Also, it has been reported that XFS and XFG are associated with systemic diseases, particularly cardiovascular alterations⁸⁸. However, there are recent reports which do not support this association^{47, 61, 88-91}.

Signs and symptoms:

IOP: > 21 mm Hg, frequently higher than in average POAG cases.
Visual field loss as in POAG; frequently severe at least in one eye.
Dandruff-like exfoliation material on the pupil border and on the surface of the anterior lens capsule except the central zone, better visualized after pupillary dilation. The pupillary collarette is irregular and typically has a moth-eaten appearance.
Pigmentary loss from the central or mid-iris and positive transillumination are possible. The angle can be open, narrow or closed; usually the TM is heavily pigmented with a blackish hue and dandruff-like particles and pigment granules may be seen in the lower angle recess.

When pigment accumulates along an undulating line on or anterior to the Schwalbe's line, this feature is called Sampaolesi's line, which is pathognomonic of XFS.
Loose zonules are frequent with occasional phacodonesis, lens subluxation and more frequent complications during cataract surgery.
Narrow or closed-angle is relatively common.

Treatment:

Decrease the IOP with all medications, laser trabeculoplasty and filtering surgery used in the treatment of POAG. Usually XFG responds well to laser trabeculoplasty⁹². To achieve target IOP usually more medications are needed than in POAG. Due to the high diurnal IOP fluctuation, to characterize untreated baseline IOP and IOP under treatment several IOP measurements are necessary. When XFG is clinically unilateral the fellow eye must be also carefully followed because there is a high probability of development of XFG⁹³.

2.3.1.1.2 Pigmentary glaucoma

Etiology:

Melanin granules cause an increase of trabecular meshwork outflow resistance and hence an elevation of IOP. The current understanding is that trabecular meshwork cells phagocytise pigment, which subsequently leads to their death⁹⁴.

Pathogenic mechanism:

Melanin pigment is released from the iris pigmented epithelium as the result of rubbing between lens zonules and posterior surface of the iris. Posterior bowing of the iris with "reverse pupillary block" configuration is noted in many eyes with pigment dispersion^{95,96}.

Classification and Terminology

Three entities can be described:

- ∞ Pigment dispersion syndrome (PDS) - ocular condition, usually bilateral characterized by dispersion of iris pigment
- ∞ Pigmentary ocular hypertension (POH) - pigment dispersion syndrome with elevated IOP and without glaucomatous optic neuropathy
- ∞ Pigmentary glaucoma (PG) - glaucomatous optic neuropathy and pigment dispersion syndrome

Epidemiology:

PG represents 1-1.5% of all glaucoma cases⁹⁷. It is more common in Caucasian myopic men. It typically diagnosed at the age of 30-50 years. The risk of developing glaucoma in patients with PDS is 25 - 50%. The estimated incidence of PDS and PG is 4.8/100 000 and 1.4/100 000 population per year respectively. The risk of developing pigmentary glaucoma from pigment dispersion syndrome is 10% at 5 years and 15% at 15 years⁹⁸.

Symptoms:

Patients may experience transient visual blurring or halos during episodes of IOP rise, particularly after exercise or pupillary dilation, uncommonly associated with mild to moderate pain.

Signs:

PDS maybe either unilateral or bilateral. Signs of PDS or PG are very deep anterior chamber with backward bowing of the peripheral iris, midperipheral iris transilluminations with a radial spoke like pattern due to pigment loss best visible with retroillumination, pigment deposition on the iris surface and lens equator among zonular insertions, pigment deposition in the corneal endothelium typically accumulating vertically as a Krukenberg spindle. The presence of Krukenberg spindle is not necessary to make the diagnosis of PDS and may occur in other conditions such as exfoliation syndrome. Gonioscopy shows a homogeneously dark brown, densely pigmented trabecular meshwork around 360° and pigment at or anterior to the Schwalbe's line, not to be confused with the Sampaolesi's line of pseudoexfoliation; dim light in the examination room is recommended in order pupillary constriction and enhance gonioscopic observation of peripheral iris shape. Ultrasound biomicroscopy (UBM) can be helpful to confirm reverse pupillary block. PDS and PG can be independently combined with primary angle closure. IOP is typically elevated with large fluctuations. Gradual decrease of IOP after 60 years of age has been reported⁹⁹.

Treatment:

- Medical treatment recommendations for PG are not different to that of POAG [I,D]. Pilocarpine is no longer a preferred drug, but if used, one should check the peripheral retina for tears [I,D].
- Laser trabeculoplasty [I,C] is effective. However, the heavily pigmented trabecular meshwork warrants power settings lower than usual [I,D]. The initially good pressure fall may be lost over time. Repeat ALT is rarely successful¹⁰⁰. c) Nd:YAG laser peripheral iridotomy (LPI) has been proposed as a means for eliminating

Classification and Terminology

reverse pupillary block (if present). The benefit from an LPI in patients with PDS and pigmentary ocular hypertension is not established¹⁰¹. d) Filtering procedures [I,D] are usually as successful as in POAG. Young myopic patients are at increased risk of hypotony maculopathy¹⁰².

Examination after exercise should be considered, especially when visual symptoms after exercises are reported. Increased pigment dispersion with posterior iris bowing during exercise is a sign of potentially progressing disease; in such patients; LPI may be considered¹⁰³.

2.3.1.1.3 Lens-induced open-angle glaucoma

Etiology:

In lens induced open angle glaucoma trabecular meshwork outflow pathways are obstructed by lens particles and/or inflammatory cells¹⁰⁴.

Pathogenic mechanism:

- Phacolytic glaucoma: the trabecular meshwork is obstructed by lens material leaking from mature or hypermature cataract
- Traumatic lens injury: the trabecular meshwork is obstructed by lens particles from a traumatically or surgically injured lens
- Phacoanaphylactic glaucoma: lens proteins lead to granulomatous uveitis affecting the trabecular meshwork.
- Sympathetic Ophthalmia: in rare cases uneventful cataract surgery in one eye can induce inflammation of the previously healthy contralateral eye leading to IOP spikes

Clinical features:

Patients usually suffer from unilateral pain with redness and inflammation. Reduced vision and elevated IOP. Signs of injured lens and/or mature/hypermature cataract or cataract surgery are present, with or without iritis (cf aqueous flare and keratic precipitates).

Treatment:

Extraction of lens or lens fragments followed by topical anti-inflammatory medication, vitrectomy if needed [I,D].

2.3.1.1.4 Glaucoma associated with intraocular haemorrhage

Etiology:

Either acute bleeding in the anterior chamber or long standing blood in the vitreous of any source can cause IOP elevation. Sickle cell trait / disease should always be considered because these patients may be at a higher risk for elevated IOP.

Pathogenic mechanism:

Large quantity of normal red blood cells (hyphaema) or haemoglobin-laden macrophages

Classification and Terminology

(haemolytic glaucoma) or degenerated red blood cells (ghost cell glaucoma) obstruct the trabecular meshwork.

Symptoms:

Pain and eye irritation.

Signs:

Elevated IOP is more common with larger hyphaemas and is more often due to recurrent haemorrhage or re-bleeding. Re-bleeding can follow traumatic hyphaema, usually after 3-7 days (incidence 5 - 10%). Patients with sickle cell disease / trait have an increased incidence of elevated IOP. They are also more prone to developing glaucomatous neuropathy and can be more difficult to treat¹⁰⁵. In haemolytic glaucoma red-tinged cells in the aqueous humour and reddish brown discoloration of the trabecular meshwork are present. "Ghost cells" occur 1 to 4 weeks after vitreous haemorrhage and reach the anterior chamber. Small khaki-coloured cells may be seen circulating in anterior chamber. Gonioscopic examination may show layering of the ghost cells over the inferior part of trabecular meshwork.

Treatment:

- Topical and systemic IOP lowering medication as needed [I,D]. It is recommended to avoid carbonic anhydrase inhibitors and hyperosmotic agents in patients with sickle cell disease.
- Conservative treatment, bed rest, topical cycloplegics and steroids, can be considered for uncomplicated hyphaema [II,D]. Antifibrinolytic agents such as tranexamic acid can reduce the risk of re-bleeding¹⁰⁶. However it is not clear whether any of the interventions have an effect on visual acuity¹⁰⁷.
- Wash-out through a paracentesis of the anterior chamber [II,D] and/or vitrectomy for removing RBCs from vitreous if IOP remains high with the risk of causing corneal blood staining and/or optic neuropathy [II,D].

2.3.1.1.5Uveitic glaucoma

Etiology:

Acute IOP elevation is typical in Posner-Schlossman syndrome or in viral infection such as HSV and VZV. Chronic IOP elevation is typical for Fuchs' uveitis, juvenile idiopathic arthritis, Behcet disease, pars planitis, sympathetic ophthalmia, sarcoidosis and syphilis.

Pathogenic mechanism:

Obstruction and oedema of the trabecular meshwork are caused by inflammatory cells, precipitates, debris, secondary scarring and neovascularization of the chamber angle. Secondary angle-closure glaucoma can be due to synechial closure of the chamber angle or seclusio pupillae with subsequent appositional angle closure. Corticoid treatment can also contribute to IOP elevation¹⁰⁸.

Symptoms:

Pain, redness, photophobia, decreased vision are possible.

Classification and Terminology

Signs:

Features depend on the underlying cause. Elevated IOP; some forms are associated with wide oscillations or periodic rise in IOP.

Treatment [I,D]:

- Topical and systemic anti-inflammatory therapy according to the underlying disease
- Topical and systemic IOP lowering medication
 - traditionally topical -blockers and CAls were used as first-line treatment.
 - prostaglandin analogues are used as first-line therapy in eyes with controlled uveitis. There are studies that support the efficacy and safety of prostaglandin analogues as IOP lowering medication in uveitic glaucoma¹⁰⁹.
- Glaucoma surgery suited for the type of inflammatory disease, ALT and SLT should be avoided^{110,111}.

2.3.1.1.6 Neovascular Glaucoma (See Secondary Angle Closure Glaucoma)

2.3.1.1.7 Glaucoma due to intraocular tumour

Etiology:

Reduced aqueous humour outflow due to primary or secondary intraocular tumours, mainly of the anterior segment.

Pathogenic mechanism:

Infiltration of the trabecular meshwork by the tumour or tumour cells floating in the aqueous humour. Trabecular meshwork obstruction due to tumour related inflammation, tumour debris, haemorrhage or pigment dispersion. Secondary angle closure glaucoma may also develop¹¹².

Symptoms and signs:

Elevated IOP. A highly variable clinical picture, combining evidence of both tumour and glaucoma.

Treatment [I,D]:

- Treatment of underlying tumour (irradiation, surgical tumour excision, enucleation)
- Topical and systemic IOP lowering medication; medical therapy is often first-line treatment while awaiting definitive treatment:
 - topical -blockers, -agonists, topical and systemic CAls are safe and effective
 - prostaglandin analogues (increasing uveoscleral outflow) and pilocarpine (increasing trabecular outflow) may theoretically promote metastasis
- Cycloablation
- Incisional glaucoma surgery indicated only after successful tumour therapy.

2.3.1.1.8 Glaucoma associated with retinal detachment

Etiology and pathogenic mechanism:

Long standing retinal detachment that leads to ischaemic neovascularization. Retinal detachment is usually associated with a reduction of IOP. Gas tamponade can elicit significant IOP spikes. Dispersed silicon oil may cause chronic IOP elevation. The trabecular meshwork may be obstructed by neovascularization caused by proliferative retinopathy, or by scarring, pigment dispersion and inflammation, or by cellular debris from retinal cells outer segments (Schwartz's syndrome). Surgery for retinal detachment can also cause glaucoma¹¹³.

Symptoms and signs:

Elevated IOP and retinal detachment are present. Redness and pain are common features.

Treatment (I, D):

- Topical and systemic IOP lowering medication
- Surgery for retinal detachment
- Consider glaucoma surgery

2.3.1.2 Open-angle glaucoma due to ocular trauma

Ocular trauma leads to glaucoma by several different mechanisms. The secondary traumatic glaucomas can be caused by both open-angle and angle-closure mechanisms. In order to identify and treat the causes of IOP elevation; careful evaluation of the ocular damage must be performed.

Etiology:

Blunt non-penetrating or penetrating trauma to the eye.

Pathogenic mechanisms:

Blunt non-penetrating trauma can lead to reduced trabecular outflow due to traumatic changes of the trabecular meshwork. Scarring and inflammation of the trabecular meshwork, obstruction by red blood cells and debris, angle recession, lens-induced glaucoma. Elevated IOP may occur a very long time after the trauma. Positive steroid response after anti-inflammatory treatment should also be considered. Penetrating injury may damage one or more intraocular structure leading to elevated IOP¹¹⁴.

Symptoms and signs:

Redness, pain, decreased vision with acute IOP elevation, or no symptoms with chronic IOP elevation. Acute or late IOP elevation (occurring months or even decades later) may follow blunt trauma.

Chemical burns, hyphaema, traumatic cataract, uveitis, angle recession, ruptured iris sphincter, iridodialysis can be present in various combinations.

Note: It is not recommended to perform gonioscopy in fresh ocular trauma to avoid compressing the eye. This examination can be delayed for several weeks.

Classification and Terminology

Treatment [I,D]:

- Anti-inflammatory
- Topical and systemic IOP lowering medication
- Long-term IOP follow up in the presence of permanent anterior segment damage.
- Glaucoma surgery

2.3.2 Iatrogenic Secondary Open-Angle Glaucomas

2.3.2.1 Glaucoma due to corticosteroid treatment

Etiology:

Topical, intravitreal as well as high dose and long-term systemic corticosteroid therapy can induce acute or chronic IOP elevation¹⁵. The risk of IOP elevation depends on the chemical structure (strength) of the steroid, dose, frequency and duration of therapy, and route of administration. The risk factors for being steroid responder are: POAG, family history of glaucoma, diabetes, myopia, rheumatoid arthritis, children and elderly patients.

Pathogenic mechanism:

Corticosteroids induce changes in the trabecular extracellular matrix (glycoproteins) which lead to decreased outflow facility. A TIGR gene modification is present¹⁶.

Symptoms:

Pain and eye irritation are possible but not at all mandatory especially in acute IOP elevation.

Signs:

Elevated IOP usually develops 2 to 6 weeks after initiating therapy, but may occur at any time. Usually IOP elevation is slowly reversed after stopping the use of corticosteroid. Corneal oedema can be present. Prolonged IOP elevation can lead to typical glaucomatous optic nerve head changes and visual field damage.

Treatment [I,D]:

- Discontinuation of corticosteroid therapy is recommended; steroid-sparing therapy of underlying condition should be considered. If this is not possible, consider switching to weaker steroid (e.g. loteprednol, fluorometholone)
- Topical and systemic IOP lowering medication
- Laser trabeculoplasty
- Glaucoma surgery may be performed in intractable cases

2.3.2.2 Secondary open-angle glaucoma due to ocular surgery and laser

Ocular surgery can cause secondary open-angle glaucoma by some of the mechanisms discussed above: intraocular haemorrhage, inflammatory reaction, lens material, pigmentary loss from uveal tissue, or trauma¹⁷.

Classification and Terminology

Pathogenic mechanism:

Open-angle glaucoma following ocular surgery or laser is a result of reduced trabecular outflow:

- IOP elevation after intraocular surgery is usually transient. The elevated IOP may be caused by: viscoelastic material, inflammatory debris, vitreous in the anterior chamber after cataract surgery, lens particles, intra-operative application of -chymotrypsin, and prostaglandin release.
- Acute onset secondary IOP elevation after Nd:YAG laser iridotomy, capsulotomy and laser trabeculoplasty. IOP elevation is usually transient, within the first 24 hours, most frequent in the first 4 hours after treatment.
- IOP elevation with open-angle following vitrectomy with silicon oil implantation develops as a result of:
 - Migration of silicon oil into anterior chamber and obstruction of the trabecular meshwork (early post-op IOP increase) usually due to overfill of oil.
 - Migration of emulsified silicon oil into anterior chamber with obstruction of trabecular meshwork where oil particles are partially phagocytised by macrophages and accumulate in the trabecular meshwork especially in the upper quadrant and can induce trabeculitis (intermediate and late onset IOP increase). Prolonged contact of silicon oil with the trabecular meshwork may cause permanent structural changes. Risk factors for developing IOP elevation following vitrectomy with silicon oil implantation include pre-existing ocular hypertension or glaucoma, diabetes mellitus, and aphakia (closed angle type)^{118,119}.
- Uveitis-glaucoma-hyphema (UGH) syndrome - IOP elevation associated with an anterior chamber intraocular lens due to induced iris root bleeding and anterior uveitis. Modern IOLs pose a significantly lower risk of inducing UGH syndrome.

Treatment [L,D]:

- Topical and systemic IOP lowering medication
- Anti-inflammatory treatment
- Removal of silicone oil may be considered in eyes with IOP elevation secondary to silicon oil emulsification. However current data suggest that removal of silicon oil is not effective in all cases and the risk of re-detachment increases. Trans-scleral cyclophotocoagulation and aqueous drainage devices seem to represent more effective options, although the latter are associated with the risk of silicon oil escape into sub-conjunctival space. Endoscopic cyclophotocoagulation in eyes requiring silicon oil removal and antiglaucoma treatment seems to be effective option. Conventional filtration surgery is associated with poor prognosis.
- Removal of the intraocular lens may be needed in case of UGH syndrome
- Glaucoma surgery according to the specific condition.

Classification and Terminology

2.3.3 Secondary Open-Angle Glaucoma Caused By Ex trabulbar Disease

2.3.3.1 Glaucoma caused by increased episcleral venous pressure

Etiology and pathogenic mechanism:

Episcleral, orbital or systemic diseases can cause the elevation of episcleral venous pressure with subsequent reduction of trabecular outflow and IOP elevation. The following disorders can be described:

- Episcleral and orbital causes: chemical burn or radiation damage of the episcleral veins, hemangioma in Sturge-Weber syndrome, Nevus of Ota, endocrine orbitopathy, orbital (retrobulbar) tumor, pseudotumor, orbital phlebitis, orbital or intracranial arteriovenous fistula
- Neurologic conditions: dural shunts, cavernous sinus thrombosis
- Other systemic causes: superior vena cava obstruction, jugular vein obstruction (radical neck dissection), pulmonary venous obstruction
- Idiopathic forms

Symptoms and signs:

IOP elevation can be acute with eye irritation and pain. Visual acuity can be decreased. Dilated, congested episcleral veins, chemosis, facial lymphedema, orbital bruit can be present. Vascular bruits are characteristic signs of A/V fistulae¹²⁰

Treatment [LD]:

- a) Treatment of the underlying disease
- b) Topical and systemic IOP lowering medication
- c) Glaucoma surgery

2.4 - PRIMARY ANGLE-CLOSURE

Scientific publications on angle-closure have suffered from the lack of a uniform definition and specific diagnostic criteria. Only in recent years has there been recognition of the need to standardize definitions of the various types.

Angle-closure is defined by the presence of iridotrabecular contact (ITC). This can be either appositional or synechial. Either can be due to any one of a number of possible mechanisms. Angle closure may result in raised IOP and cause structural changes in the eye. Primary angle-closure (PAC) is defined as an occludable drainage angle and features indicating that trabecular obstruction by the peripheral iris has occurred. The term glaucoma is added if glaucomatous optic neuropathy is present: Primary angle-closure glaucoma (PACG). The main reason to distinguish Primary angle-closure glaucoma from Primary open-angle glaucoma is the initial therapeutic approach (i.e. iridotomy or iridectomy) and the possible late complications (synechial closure of the chamber angle) or the complications resulting when this type of glaucoma undergoes filtering surgery (uveal effusion, cilio-lenticular block leading to malignant glaucoma)^{121,122}.

The prevalence of primary angle closure glaucoma (PACG)

Ethnic background is one of the major factors determining susceptibility to primary angle-closure (PAC). Population surveys show that PAC is more common among people of Asian descent than those from Europe. Among people aged 40 years and over, the prevalence of PAC ranges from 0.1% in Europeans^{123,124} through 1.4% in East Asians^{123,124} and up to 5% in Greenland Inuit¹²⁵. Of those over 40 years old in European derived populations, 0.4% are estimated to have PACG. Three-quarters of cases occur in female subjects. There are 1.60 million people in Europe and 581 000 people in the USA with PACG¹²⁶.

Primary glaucoma cases should be examined and the anterior chamber angle shown to be open on gonioscopy before PACG is excluded¹²⁷.

Provocative Tests

In general provocative tests for angle-closure provide little additional information since even when negative they may not rule out the potential for angle-closure. In addition they may be hazardous, triggering an acute angle-closure attack even while the patient is monitored.

Classification and Terminology

2.4.1 Primary Angle-Closure (PAC)

Angle-closure is defined by the presence of iridotrabecular contact (ITC). Gonioscopy remains the standard technique for identifying ITC. Primary angle-closure (PAC) results from crowding of the anterior segment, and as such, usually occurs in eyes with smaller than average anterior segment dimensions. Pathological angle-closure is defined by the presence of ITC combined with either elevated intraocular pressure (IOP) or peripheral anterior synechiae (PAS), or both. The absence of ocular diseases which may induce the formation of PAS such as uveitis, iris neovascularisation, trauma and surgery, defines primary angle-closure. Additionally, angle-closure resulting from the action of forces at the level of the lens or behind the lens is usually regarded as secondary (i.e. cataract, massive vitreous haemorrhage, and silicone oil or gas retinal tamponade) as the successful management is aimed at the underlying lens or posterior segment pathology. Angle-closure may impair aqueous outflow through simple obstruction of the trabecular meshwork (TM), or by causing irreversible degeneration and damage of the TM.

2.4.1.1 Natural History of PAC

PAC becomes more likely as the separation between the iris and TM decreases¹²⁸. The risk of iridotrabecular contact in a “narrow” angle begins to increase once the iridotrabecular angle is $\leq 20^{\circ}$ ¹²⁹. With angles of 20° or less, signs of previous angle-closure, such as PAS or iris pigment on the TM, should be carefully sought as signs of previous closure. Most angle-closure occurs asymptotically. Although symptoms of pain, redness, blurring of vision or haloes may help identify people with significant angle-closure, the sensitivity and specificity of symptoms for identifying angle-closure are very poor. The most commonly identified sign which indicates that treatment is required is ITC. There is not a precise extent of gonioscopically evident ITC which will dictate the indication to treatment for all cases.

An international group of experts reached a consensus that 2 quadrants or more of ITC is an indication for prophylactic treatment¹³⁰ [II, D]. Clearly, in established disease with high IOP, established PAS or glaucomatous optic neuropathy, any potential for angle-closure should be considered and treated on individual merits.

2.4.1.2 Staging of Primary Angle-closure¹²³

- a) **Primary Angle-closure Suspect (PACS)**
Two or more quadrants of iridotrabecular contact (ITC), normal IOP, no PAS, no evidence of glaucomatous optic neuropathy (GON).
- b) **Primary Angle-closure (PAC)**
Iridotrabecular contact resulting in PAS and/or raised IOP. No evidence of GON.
- c) **Primary Angle-closure Glaucoma (PACG)**
Iridotrabecular contact causing GON; PAS and raised IOP may be absent at the time of initial examination.

2.4.1.3 Ocular Damage in Angle-closure

Primary angle-closure (PAC) may cause ocular tissue damage in many ways. Corneal endothelial cell loss occurs after symptomatic “acute” angle-closure. With very high IOP values the iris may suffer ischaemic damage to musculature causing iris whirling (distortion of radially orientated fibres) and/or a dilated, unresponsive pupil. The lens epithelium may suffer focal necrosis causing anterior sub-capsular or capsular opacity of the lens associated with focal epithelial infarct called “Glaukomflecken”. The trabecular meshwork can be damaged by the formation of PAS, or as the result of long-standing appositional closure. Optic neuropathy in angle-closure may manifest in at least 2 ways. After an “acute” symptomatic episode, the disc may become pale but flat, suggesting an anterior ischaemic optic neuropathy. Typical glaucomatous optic neuropathy manifests in with an excavated surface and a pattern of visual field loss indistinguishable from open-angle glaucoma. Angle-closure accounts for 50% of all glaucoma blindness worldwide, and is probably the most visually destructive form of glaucoma.

2.4.1.4 Outcome following treatment

In asymptomatic (“chronic”) angle-closure, a high presenting pressure (>35 mmHg), more than 6 clock hours of peripheral anterior synechiae and/or established glaucomatous optic neuropathy are signs that a case of angle-closure will not respond fully to a laser iridotomy¹³¹, and that a trabeculectomy may be needed to control pressure” [II,D].

2.4.1.5 Mechanisms of angle-closure

It is important to identify secondary causes of narrow or closed-angles, such as phakomorphic, uveitic and neovascular cases, as the management of these cases is initially directed at controlling the underlying disease. In isometric eyes it is helpful to compare axial anterior chamber depths of the two eyes. Asymmetry of > 0.2 mm (3 standard deviations) is suggestive of a secondary pathological process. A-mode or ultrasound biomicroscopy may be helpful in measuring axial dimensions (length, AC depth and lens thickness) and defining anatomical relationships. In primary angle-closure these will be the same in each eye. Mechanisms responsible for angle-closure are described in terms of anatomical location of obstruction to aqueous flow, successively, at the pupil, the iris and ciliary body, the lens and behind the lens. This is also order of decreasing frequency of each mechanism. Two mechanisms may co-exist, especially levels I and II (i.e. pupil and iris/ciliary body). Often, one mechanism predominates.

- I. Pupilary block mechanism
Pupilary block is the predominant mechanism in around 75% of cases of primary angle-closure. Pupilary block is an exaggeration of a physiological phenomenon in which the flow of aqueous from the posterior chamber through the pupil to the

Classification and Terminology

anterior chamber is impeded causing the pressure in the posterior chamber to become higher than the pressure in the anterior chamber. As a result, the peripheral iris bows forward and comes into contact with the trabecular meshwork and/or peripheral cornea.

In a minority of cases, this becomes a self-perpetuating cycle with obstruction of trabecular outflow leading to a rise in IOP up to 50–80 mmHg. When total trabecular obstruction occurs rapidly (within a few hours), it causes the symptoms and signs of acute angle-closure (AAC).

The increased resistance to trans-pupillary aqueous flow is believed to result from co-activation of both sphincter and dilator muscles, causing the pupil margin to grip the anterior surface of the lens. This may occur in response to physiological stimuli, such as reading in poor light, or pharmacologically, such as with miotic therapy and concomitant dilator muscle stimulation by phenylephrine (the Mapstone provocation test)¹³². In most cases, the predisposition to pupil block is created by a narrow anterior segment and the age-related increase of lens volume (See Ch. 2.5.1 and 2.5.3).

The prevalence of PACs is higher in elderly people women and in some races (especially East Asians). There is a weaker association with hypermetropia, exfoliation syndrome, diabetes and retinitis pigmentosa.

II. Anomalies at the level of the iris and/or ciliary body (“plateau iris configuration”)

This group of anterior, non-pupil-block mechanisms are sometimes erroneously referred to under the umbrella term “plateau iris”. They are the result of variations in iris and ciliary body anatomy that brings the peripheral iris into contact with the trabecular meshwork. These include a thicker iris, a more anterior iris insertion and a more anterior ciliary body position. These anatomical factors predict failure of a laser iridotomy to open an appositionally closed angle¹³³.

Anteriorly positioned ciliary processes cause “typical” plateau iris configuration¹³⁴. Plateau iris “syndrome” should be differentiated from plateau iris configuration. The “configuration” refers to a situation in which the iris plane is flat and the anterior chamber is not shallow axially. In most cases, the angle-closure glaucoma associated with the plateau iris configuration is cured by a peripheral iridectomy. “Plateau iris syndrome” refers to a post-laser condition in which a patent iridotomy has removed the relative pupillary block, but gonioscopically confirmed angle closure recurs without shallowing of the anterior chamber axially. Plateau iris syndrome is rare compared to the configuration, which itself is not common. It usually occurs in a younger age group than pupillary-block angle-closure. The treatment is laser iridoplasty or the long-term use of pilocarpine postoperatively as long as it is needed [II,D]. This syndrome must be considered in the differential diagnosis when the intraocular pressure rises unexpectedly following an adequate peripheral iridectomy procedure for angle-closure glaucoma¹³⁵. Ideally, treatment should be instituted before synechial closure of the angle occurs [II,D].

III. Anomalies at the Level of the Lens

The most widely recognised risk factor for primary angle-closure is a shallow anterior chamber. The anterior surface of the lens marks the depth of the anterior chamber, and as such, PAC patients typically have a thicker, more anteriorly positioned lens

than people with wide open angles. Nuclear sclerotic cataract is a frequent finding in primary angle-closure. If a separate pathological or iatrogenic process causes the lens to suddenly increase in thickness (e.g. "classic" diabetic or post-traumatic cataract), become more anteriorly positioned (retinal gas or oil tamponade) or subluxate (Marfan syndrome or trauma), this may cause secondary angle-closure (See Ch. 2.5.1 and 2.5.3).

IV. Anomalies posterior to the Lens (Aqueous misdirection syndrome)

In rare cases, aqueous misdirection can complicate the management of primary angle-closure. This may occur following trabeculectomy, lens extraction, laser iridotomy and other surgical procedures. Forward movement of the lens iris diaphragm causes secondary angle-closure resulting in IOP elevation. These cases, typically have very small eyes (axial length <21 mm) and higher hypermetropic refraction ($> +6D$). It is believed that the ciliary processes come into contact with the lens equator, and/or a firm zonule/posterior capsule diaphragm, causing misdirection of aqueous into the vitreous^{135, 136}. As a consequence, the lens/iris diaphragm is pushed forward and occludes the anterior chamber angle. After iridotomy or iridectomy, the use of miotics raises the IOP, whereas the use of cycloplegics reduces the IOP. This 'inverse' or 'paradoxical' reaction to parasymphomimetics should be tested only after iridotomy has been performed. Ultrasound biomicroscopy can demonstrate abnormal posterior chamber anatomy in these rare cases (See Ch. 2.5.3). Asymmetry of anterior chamber depth is a cardinal sign of secondary (types III and IV) angle-closure.

Systemic drugs and angle-closure

Systemic drugs which may induce angle-closure in pre-disposed individuals are: nebulised bronchodilators (ipratropium bromide and/or salbutamol), selective serotonin re-uptake inhibitors (SSRI's), tricyclic antidepressants, proprietary cold and flu medications, muscle relaxants, anti-epileptics (topiramate) and other agents with a parasymphomimetic and sympathomimetic action¹³⁷.

2.4.1.6 Demographic risk factors for Primary Angle-Closure^{135,138}

- ∞ Older age
- ∞ Female
- ∞ Asian and Eskimoan Race

Family history of primary angle-closure: family screening is vital in these families as robust evidence now exists for significant increased risk of angle closure in family members of an affected patient: first degree relatives may have a 1 in 4 risk of a PAC disease requiring treatment¹³⁹.

Classification and Terminology

2.4.1.7 Descriptions of subtypes:

Primary angle-closure has previously been divided into 5 clinical subtypes according to mode of presentation. *There is debate on whether this approach to classification is useful in determining the prognosis or optimal management.*

- ∞ Primary Angle-Closure Suspect (PACS)
- ∞ Acute Angle-Closure (AAC)
- ∞ Intermittent Angle-Closure (IAC)
- ∞ Chronic Angle-Closure Glaucoma (CACG)
- ∞ Status Post-Acute Angle-closure Attack

2.4.1.7.1 Primary Angle-Closure Suspect (PACS) or “occludable” angle

Etiology and pathomechanism:

Pupillary block or plateau iris configuration; each component plays different roles in different eyes (See Ch. 2.4.1.5).

Features:

Signs:

- ∞ Two or more quadrants of iridotrabecular contact (ITC)
- ∞ Normal IOP
- ∞ No peripheral anterior synechia (PAS)
- ∞ No evidence of glaucomatous optic neuropathy (GON)
- ∞ No glaucomatous visual field defect

The fellow eye of a documented non-secondary angle-closure is considered capable of occlusion.

Treatment:

PACS or “occludable angle” is a clinical assessment. Whether to treat or not is the responsibility of the ophthalmologist. There is not a precise extent of gonioscopically evident ITC which will dictate the indication to treatment for all cases.

If a PAC suspect has narrow angle with two or more quadrants of ITC but no synechial angle closure, the treatment to offer the patient is laser peripheral iridotomy (LPI) followed by argon laser peripheral iridoplasty (ALPI) in cases with plateau iris configuration [I,D].

The same applies to fellow eyes of primary angle-closure [I,C]. All cases must be assessed individually [I,D]. In general, the risks of treatment are to be balanced against the perceived risk of angle-closure.

2.4.1.7.2 Acute Angle-Closure (AAC) with pupillary block mechanism

Etiology:

Circumferential iris apposition to the trabecular meshwork with rapid and excessive increase in IOP that does not resolve spontaneously.

Pathomechanism:

See Ch. 2.4.1.5

Features:

Signs:

- ∞ IOP >21 mmHg, often to 50-80 mmHg.
- ∞ Decreased visual acuity
- ∞ Corneal oedema, initially mostly epithelial oedema. Shallow or flat peripheral anterior chamber
- ∞ Peripheral iris pushed forward and in contact with Schwalbe's line. Gonioscopy: iridotrabecular contact 360°
- ∞ Pupil mid-dilated and reduced or no reactivity
- ∞ Venous congestion and ciliary injection
- ∞ Fundus: disc oedema, with venous congestion and splinter haemorrhages, or the disc may be normal or show glaucomatous excavation
- ∞ Bradycardia or arrhythmia
- ∞ Gonioscopy clues from the other eye

Symptoms:

- ∞ Blurred vision, "halos" around lights
- ∞ Pain
- ∞ Frontal headache of variable degree on the side of the affected eye
- ∞ Nausea and vomiting, occasionally
- ∞ Palpitations, abdominal cramps, occasionally

Treatment options:

See also flowchart FC VII-VIII

- A. Medical treatment
- B. Laser peripheral iridotomy (LPI)
- C. Argon Laser Peripheral Iridoplasty (ALPI)
- D. Lens Extraction
- E. Trabeculectomy
- F. Anterior Chamber Paracentesis
- G. Goniosynechialysis (GSL)

Iridotomy or iridectomy together with medical treatment is the preferred definitive treatment of acute angle-closure glaucoma with a pupillary block component [I,D]

A: Medical Treatment [I,D]

Medical treatment serves to lower IOP, to relieve the symptoms and signs so that laser iridotomy or iridectomy is possible

Medical therapy aims for

1. withdrawal of aqueous from vitreous body and posterior chamber by hyperosmotics
2. pupillary constriction to open the chamber angle
3. reduction of aqueous production reduction of inflammation.

Classification and Terminology

All the above steps of medical therapy should be implemented concurrently [I,D]

Consider contraindications to each of the medications to be used

- Reduction of aqueous production
 - acetazolamide 10 mg/Kg intravenously or orally. Topical carbonic anhydrase inhibitors (CAIs) are not potent enough to break the pupillary block
 - topical alpha-2 agonists
 - topical beta-blockers
- Dehydration of vitreous body

Hyperosmotics are the effective agents but carry significant systemic risk in some patients: patients must be evaluated for heart or kidney disease because hyperosmotics increase blood volume which increases the load in the heart [II,D]. Glycerol may alter glucose blood levels and should not be given to diabetics (FC VII) [I,D]

- glycerol 1.0 - 1.5 g/Kg orally
- mannitol 1.0 - 1.5 g/Kg intravenously

- Pupillary constriction [I,D]
 - pilocarpine 1% or 2% or aceclidine 2% twice or three times within 1 hour

Note: while the sphincter is ischaemic and the pupil non-reactive to light for sphincter paresis, multiple applications of topical parasympathomimetics is not helpful, will not cause pupillary constriction and may cause forward rotation of the ciliary muscle, thereby increasing the pupillary block. Since miotics in large doses can cause systemic side effects due to trans-nasal absorption leading to abdominal spasms and sweating, intensive topical parasympathomimetics are no longer indicated to treat this condition. Miotics are likely to constrict the pupil only after OP has been lowered.

 - dapiprazole 0.5%
 - Alpha-1 blockers relax the dilator muscle. They do not reduce pupil size when the sphincter muscle is paretic.
- Reduction of inflammation
 - Topical steroid every 5 minutes for three times, then 4-6 times daily, depending on duration of raised IOP and severity of inflammation.

B: Surgical Treatment

- Neodymium YAG laser iridotomy
 - Laser iridotomy should be attempted if the cornea is sufficiently clear [I,C]. Argon laser iridotomy is rarely performed nowadays but thermal laser pre-treatment (e.g., argon) of dark irides reduces total YAG energy required¹²⁷ [II,B]
- Surgical iridectomy
 - 1) Transcorneal approach.
 - Advantages:
 - No conjunctival scarring
 - A water-tight self-sealing incision is possible

Classification and Terminology

- Disadvantages:
 - Technically more difficult in dilated fixed pupil and flat anterior chamber
 - More traction on iris with increased risk of haemorrhage
- 2) Corneoscleral approach
 - Advantages:
 - Iridectomy can be basal
 - Disadvantages:
 - Conjunctival wound may lead to scarring compromising the outcome of a filtering procedure which may become necessary at a later stage
 - Insufficient wound closure and aqueous misdirection may occur in rare cases
- 3) General advantages of surgical iridectomy:
 - It can be performed even when the cornea is cloudy
 - It allows deepening of the anterior chamber, breaking freshly formed PAS
- 4) General disadvantages of surgical iridectomy:
 - All the potential risks of any intraocular procedure in an eye with angle closure

C: Argon Laser Peripheral Iridoplasty (ALPI)

There is now some evidence from randomised controlled trials that ALPI can break an attack of acute angle closure as or more swiftly than medical therapy¹⁴⁰. Many glaucoma specialists now routinely use ALPI if topical treatment + acetazolamide have not broken an attack within an hour, prior to considering hyper-osmotics. ALPI is also a useful procedure to eliminate appositional angle closure resulting from mechanisms other than pupillary block (i.e: plateau iris configuration)¹⁴¹. Diode Laser Peripheral Iridoplasty has greater penetration of an oedematous cornea but has been less extensively studied.

Anterior chamber paracentesis is being evaluated to break the attack in cases that are refractory to medical management¹⁴².

D: Lens extraction. See FC VII

Clinical reports of phacoemulsification with posterior chamber intraocular lens implantation in the treatment of acute, chronic, and secondary angle-closure +/- glaucoma describe very favourable results. The appropriate role for lensectomy in the management of primary angle closure, however, still remains unproven. The first case-series study showed that cataract extraction was associated with a good reduction in IOP and a reduction in the number of medications required to control IOP¹⁴³.

A few prospective case series or randomized clinical trials have been performed¹⁴³⁻¹⁴⁶ or are ongoing¹⁴⁷ to determine the value and comparative risks and efficacy of lens surgery, both clear lens extraction and cataract surgery, versus medical therapy, laser peripheral iridotomy, laser iridoplasty, and filtration procedures for the treat-

Classification and Terminology

ment of acute and chronic primary angle closure and for the prevention of chronic angle-closure glaucoma, both after and instead of laser peripheral iridotomy. Cataract surgery in PACG is generally more challenging and prone to complications than in normal eyes or eyes with POAG because of the shallow AC, larger lens, corneal oedema, poorly dilated or miotic pupil, extensive posterior synechiae, lower endothelial cell count, weaker zonules, especially after an acute angle closure attack.

In an eye with a clear lens: laser PI first. If the angle does not open and IOP not well controlled with unquestionable glaucomatous damage, consider to proceed with phacoemulsification and IOL implantation [I,D].

E: Trabeculectomy

Trabeculectomy in chronic PACG is also associated with higher risk of postoperative anterior chamber shallowing, malignant glaucoma, and a significant rate of cataract formation compared to POAG¹³⁷. Even when filtration surgery has successfully reduced the IOP, the ailing trabecular meshwork does not regain its function, and so the disease is not cured.

Combined lens extraction and trabeculectomy

In a study in CACG eyes with coexisting cataract, combined phacotrabeculectomy resulted in significantly more surgical complications than phacoemulsification alone. Visual acuity or disease progression did not differ between the 2 treatment groups¹⁴⁸.

F: Anterior Chamber Paracentesis^{139, 142}

- Rapidly lowers IOP in APAC
 - Instantaneous relief of symptoms
 - Prevention of further optic nerve and trabecular meshwork damage secondary to the acutely elevated IOP
 - The IOP-lowering benefit may decrease by 1 hour after the procedure
 - Anti-glaucoma medications are necessary to maintain IOP control.
- Paracentesis will not directly break the pupillary block but can allow the cornea to clear permitting to perform LPI

Possible complications include

- Excessive shallowing of the anterior chamber
- Puncture of iris, lens
- Choroidal effusion
- Haemorrhage due to the sudden decompression

G: Goniosynechialysis¹³⁸

Often performed with other procedures such as lens extraction, to detach synechia from the angle, in eyes with minimal to moderate optic nerve damage. The procedure may be complicated by:

- hypHEMA
- fibrinous inflammation and
- recurrent synechial closure of the angle

2.4.1.7.3 Acute Angle-Closure (AAC) with plateau iris configuration (See FC VII)

In plateau iris configuration the iris plane is flat and the anterior chamber is not shallow axially. (See above under Staging of Primary Angle-closure).

Medical treatment [I,D]:

- Pupilary constriction to pull the peripheral iris centripetally
- In plateau iris configuration, a modest pupilary constriction may prevent further angle-closure
 - pilocarpine 1%, aceclidine 2%, carbachol 0.75%
 - dapiprazole 0.5%

Surgical treatment [I,D]:

- Iridotomy is essential to confirm the diagnosis because it eliminates any pupilary block component
- Argon Laser Peripheral Iridoplasty (ALPI) stretches the iris and widens the chamber angle¹⁴⁹.

“Plateau iris syndrome” refers to a post-laser iridotomy condition in which a patent iridotomy has removed the relative pupilary block, but gonioscopically confirmed angle closure recurs without central shallowing of the anterior chamber. Isolated plateau iris syndrome is rare compared to the plateau configuration, which itself is not common. It usually occurs in a younger age group than pupilary-block angle-closure. The treatment is laser iridoplasty or the long-term use of pilocarpine postoperatively [I,D]. This condition must be considered in the differential diagnosis when the intraocular pressure rises unexpectedly following an adequate peripheral iridectomy procedure for angle-closure glaucoma¹³⁵.

2.4.1.7.4 Intermittent Angle-Closure (IAC)

Etiology:

Similar but milder clinical manifestations than AAC, it resolves spontaneously.

Pathomechanism:

See above Ch. 2.4.1.5

Features:

Signs:

- ∞ May vary according to amount of iridotrabeal contact of chamber angle and mimic acute angle-closure in a mild form
- ∞ When not on miotics, pupil is round and reactive
- ∞ The optic disc rim may show atrophy with an afferent pupilary defect

Symptoms:


- ∞ Mild, intermittent symptoms of acute angle-closure type

Classification and Terminology

Treatment:

Pupillary constriction, iridotomy, iridoplasty or lens extraction are to be considered according to the main mechanism determining angle occlusion [I, D]

FC VII - Management of Acute Primary Angle Closure Attack



Classification and Terminology

Iridectomy

* Aqueous
Humor

2.4.1.7.5 Chronic Angle-Closure Glaucoma (CACG) (See FC VIII)

Etiology:

Permanent synechial closure of any extent of the chamber angle as confirmed by indentation gonioscopy.

Pathomechanism:

See Ch. 2.4.1.5

Features:

Signs:

- ∞ Peripheral anterior synechiae of any degree at gonioscopy
- ∞ IOP elevated to a variable degree depending on the extent of iridotrabecular contact, above 21 mmHg
- ∞ Visual acuity according to functional status (may be normal)
- ∞ Damage of optic nerve head compatible with glaucoma
- ∞ Visual field defects "typical" of glaucoma may be present
- ∞ Superimposed intermittent or acute iridotrabecular contact possible

Symptoms:

- ∞ Visual disturbances according to functional states.
- ∞ Usually no pain; sometimes discomfort
- ∞ Transient "halos" when intermittent closure of the total circumference causes acute IOP elevations

Treatment:

Medical treatment alone is contraindicated as all patients require relief of pupil block by iridotomy, iridectomy or lens extraction [I,D]. If the synechial closure is less than half the circumference, iridectomy/iridotomy may be sufficient.

Since complications of iridotomy are uncommon, its use as the initial procedure is justified in practically every case [I,D]. Argon laser trabeculoplasty is contraindicated as it may increase synechial angle-closure [I,D]. Lens removal may be considered at all stages and can lead to relief of pupil block and sufficient IOP control [II,D].

If IOP cannot be controlled medically after breaking pupil block (with or without lens extraction), a filtering procedure is indicated [II,D]. These eyes are more frequently prone to develop posterior aqueous misdirection and the necessary precautions must be taken when considering surgery.

2.4.1.7.6 Status Post-Acute Angle-closure Attack

Etiology:

Previous episode of acute angle-closure attack

Pathomechanism:

See Ch. 2.4.1.5

Classification and Terminology

Features:

Signs:

- ∞ Patchy iris atrophy/iris torsion/spiralling posterior synechiae
- ∞ Pupil either poorly reactive or non-reactive
- ∞ “Glaukomflecken” of the anterior lens surface
- ∞ Peripheral anterior synechiae on gonioscopy
- ∞ Endothelial cell count can be decreased


Therapy:

Management according to angle, lens, IOP and disc/visual field. In case of cataract surgery, non dilatable pupil, low endothelial cell count and loose zonules are of concern.

FC VIII - Management of Chronic Angle Closure

IDENTIFY THE PATHOPHYSIOLOGICAL MECHANISM(S) RESPONSIBLE

Make sure a **patent iridotomy** is present/made before considering mechanisms other than pupillary block



* Combined with zonulotomy+iridotomy in pseudophakia

2.5 - SECONDARY ANGLE-CLOSURE

There are many different causes of secondary angle-closure and the clinical signs vary according to the underlying condition. For example in secondary acute angle-closure, the chamber angle is closed by iridotrabecular contact that can be reversed, whereas in chronic secondary angle-closure, the angle-closure is irreversible due to peripheral anterior synechiae.

A complete discussion of these topics is outside the scope of this text.

2.5.1 Secondary Angle-Closure With Pupillary Block

Etiology:

The following is a limited list of other etiologies for relative or absolute pupillary block:

- ∞ Enlarged, swollen lens (cataract, traumatic cataract)
- ∞ Anterior lens dislocation (trauma, zonular laxity; Weil-Marchesani's syndrome, Marfan's syndrome etc.)
- ∞ Posterior synechiae, seclusion or occlusion of the pupil
- ∞ Protruding vitreous face or intravitreal silicone oil in aphakia
- ∞ Microspherophakia
- ∞ Miotic-induced pupillary block (also the lens moves forward)
- ∞ IOL-induced pupillary block; anterior chamber IOL, phakic intraocular lens (PIOL), anteriorly dislocated posterior chamber intraocular lens (PC-IOL)¹⁵⁰

Pathomechanism:

Pupillary block pushes the iris forward to occlude the angle. In iritis or iridocyclitis, the development of posterior synechiae may lead to absolute pupillary block with consequent forward bowing of the iris or "iris bombe". Acute secondary angle-closure glaucoma may result.

Features:

- IOP>21 mmHg
- Disc features compatible with glaucoma

Treatment:

Several steps may be considered, according to the clinical picture of causative mechanisms [1, D]

- Topical and systemic IOP lowering medication
- Nd:YAG laser iridotomy
- Peripheral surgical iridectomy
- Lens extraction, vitrectomy
- Discontinuing miotics in miotic-induced pupillary block
- Pupillary dilation
- Nd:YAG laser synechiolysis of posterior synechiae

Classification and Terminology

2.5.2 Secondary Angle-Closure With Anterior “Pulling” Mechanism Without Pupillary Block

Pathomechanism:

The iridobulbar meshwork is obstructed by iris tissue or a membrane. The iris and/or a membrane are progressively pulled forward to occlude the angle.

Features:

- IOP > 21 mmHg
- Disc features compatible with glaucoma

2.5.2.1 Neovascular glaucoma

The iridobulbar fibrovascular membrane is induced by ocular microvascular disease with retinal ischemia; initially the neovascular membrane covers the angle, causing a secondary form of open angle glaucoma (See Ch 2.3 Secondary Open Angle Glaucoma)

Treatment [II, D]:

- Topical atropine or equivalent
- Topical steroid initially
- Topical and systemic IOP lowering medication as needed
- Retinal ablation with laser or cryotherapy
- Cyclodestruction
- Filtering procedure with antimetabolites
- Aqueous drainage devices
- Miotics are contraindicated

The intravitreal injection of anti-VEGF molecules has shown benefit for this indication [II, C] and is in widespread use.

2.5.2.2 Iridocorneal endothelial syndrome

Iridocorneal Endothelial (ICE) Syndrome, with progressive endothelial membrane formation and progressive iridotrabecular adhesion. Peripheral anterior synechiae, due to prolonged primary angle-closure; this is theoretically a primary angle-closure.

Treatment [III, D]:

- Topical and systemic IOP lowering medications as needed
- Filtering procedure, with antimetabolite according to risk factors
- Aqueous drainage device

2.5.2.3 Posterior polymorphous dystrophy

Treatment [II, D]:

- a) Topical and systemic IOP lowering medication as needed
- b) Filtering procedure, with antimetabolite according to risk factors

2.5.2.4 Epithelial and fibrous ingrowth *after* anterior segment surgery or penetrating trauma

Epithelial and fibrous ingrowth after anterior segment surgery or penetrating trauma
Inflammatory membrane.

Treatment [II, D]:

- a) Topical and systemic IOP lowering medication as needed
- b) Excision, destruction of the immigrated tissue
- c) Filtering procedure, with antimetabolite according to risk factors
- d) Aqueous drainage device
- e) Cyclodestruction

2.5.2.5 Inflammatory membrane

Treatment [II, D]:

- a) Anti-inflammatory medications and cycloplegics
- b) Topical and systemic IOP lowering medication as needed
- c) Filtering procedure with antimetabolite
- d) Aqueous drainage device
- e) Cyclodestruction

2.5.2.6 Peripheral anterior synechiae *after* ALT and endothelial membrane covering the trabecular meshwork late *after* ALT

After argon laser trabeculoplasty (ALT), early and late peripheral anterior synechiae and endothelial membrane covering the trabecular meshwork

Treatment [II, D]:

- a) Topical and systemic IOP lowering medication as needed
- b) Filtering procedure

2.5.2.7 Aniridia

Treatment [II, D]:

- a) Topical and systemic IOP lowering medication as needed
- b) Trabeculectomy

Classification and Terminology

- c) Filtering procedure with antimetabolites
- d) Aqueous drainage device
- e) Cycloablation

2.5.3 Secondary Angle-Closure With Posterior 'Pushing' Mechanism Without Pupillary Block

2.5.3.1 Aqueous misdirection (also known as cilio-lenticular block, ciliary block or malignant glaucoma)

Etiology:

Angle-closure is caused by the ciliary body and iris rotating forward. Aqueous misdirection, or malignant glaucoma, is a rare type of secondary angle-closure glaucoma most commonly encountered after filtering surgery. The syndrome, also known as ciliary block glaucoma, can occur spontaneously or following any type of intraocular surgery.

Pathomechanism:

- ∞ The lens may be proportionally abnormally large or swollen, "phacomorphic glaucoma"
- ∞ Aqueous humour accumulates in the vitreous body (posterior aqueous humour misdirection) or behind and around the crystalline lens (perilenticular misdirection) or behind the iridocapsular diaphragm or posterior chamber intraocular lens (PCL) after extracapsular cataract surgery, with or without PCL implantation, "retrocapsular misdirection"
- ∞ Frequently precipitated by ocular surgery and flat anterior chamber
- ∞ Predisposition may be similar in both eyes particularly in small eyes

Treatment:

Medical treatment

- a) Parasympatholytics (atropine, cyclopentolate) both initially and for long-term pupillary dilation and cycloplegia [I,C]
 - b) Aqueous production suppressants given orally and/or topically [I,D]
 - c) Hyperosmotics (Ch. 3.3.1.3) [I,D]
- Miotics are contraindicated!

Surgical treatment

- a) A patent iridotomy must be present or, if not present, iridotomy should be performed [I,D]
- b) YAG laser vitreolysis/capsulotomy, especially in aphakia, pseudophakia [I,C]
- c) Anterior vitrectomy, especially in aphakia, pseudophakia [I,C]
- d) Cyclo diode laser
- e) In selected cases lens extraction [II,D]

2.5.3.2 Iris and ciliary body cysts, intraocular tumors

Treatment:

- a) Tumour irradiation or excision
- b) Filtering surgery
- c) Cyclodestruction

2.5.3.3 Silicon oil or other tamponading fluids or gas implanted in the vitreous cavity¹³⁸

Treatment:

- a) Topical/systemic IOP lowering medications as needed
- b) Silicon oil or gas aspiration
- c) Filtering surgery
- d) Drainage device
- e) Cyclodestruction

2.5.3.4 Uveal effusion^{151,152}

It is due to:

- Inflammation as in scleritis, uveitis, HIV infection
- Increased choroidal venous pressure as in nanophthalmos, scleral buckling, panretinal photocoagulation, central retinal vein occlusion, arterio-venous communication
- Tumor

Treatment:

- a) Anti-inflammatory medication (for 1)
- b) Topical and systemic IOP lowering medication as needed (for 1,2 and 3)
- c) Relaxation of scleral buckling: vitrectomy, sclerectomy in nanophthalmus (for Tumor excision or irradiation (for 3)
- d) Cyclodestruction

2.5.3.5 Retinopathy of prematurity (stage V)

Features:

Signs and Symptoms:

- Variable discomfort, pain, redness, corneal oedema IOP ≥ 21 mmHg
- Axially shallow anterior chamber

Treatment:

- a) Topical and systemic IOP lowering medications
- b) Cyclodestruction
- c) Filtering procedure with or without antimetabolite
- d) Drainage devices

Classification and Terminology

2.5.3.6 Congenital anomalies that can be associated with secondary glaucoma

These conditions are extremely variable in pathogenesis, clinical presentation and required management; an extensive discussion is outside the scope of this chapter.

Etiology:

Familial iris hypoplasia, anomalous superficial iris vessels, aniridia, Sturge-Weber syndrome, neurofibromatosis, Marfan's syndrome, Pierre Robin syndrome, homocystinuria, goniodysgenesis, Lowe's syndrome, microcornea, microspherophakia, rubella, broad thumb syndrome, persistent hyperplastic primary vitreous.

Pathomechanism:

Angle-closure is caused by pushing forward the ciliary body and iris. Increase of volume of the posterior segment of the eye.

Features:

Signs and Symptoms:

- IOP > 21 mmHg
- Pain, redness, corneal oedema
- Axially shallow anterior chamber
- Laser iridotomy and surgical iridectomy are not effective

Some differential diagnoses:

Acute IOP elevation with corneal oedema but open-angle may result from Posner Schlossman syndrome (iridocyclitic crisis), or from endophthalmitis/trabeculitis as in disciform herpetic keratitis.
Neovascular glaucoma may be associated with an open or closed-angle and may mimic some signs and the symptoms of acute angle-closure.

Some differential diagnoses:

Acute IOP elevation with corneal oedema but open-angle may result from Posner Schlossman syndrome (iridocyclitic crisis), or from endophthalmitis/trabeculitis as in disciform herpetic keratitis.
Neovascular glaucoma may be associated with an open or closed-angle and may mimic some signs and the symptoms of acute angle-closure.

Treatment:

Treatment to be adapted to the primary anomaly, the mechanism of IOP elevation and the quality of life of the patient.

References

1. Papadopoulos M, Khaw PT. Advances in the management of paediatric glaucoma. *Eye (Lond)* 2007;21(10):1319-25.
2. Weinreb RN, Papadopoulos, M. Consensus on Childhood glaucoma. Amsterdam: Kugel publications, 2013.
3. Alshekheh A, Klink J, Klink T, et al. Long-term results of surgery in childhood glaucoma. *Graefes Arch Clin Exp Ophthalmol* 2007;245(2):195-203.
4. Grehn F. Congenital glaucoma surgery: a neglected field in ophthalmology? *Br J Ophthalmol* 2008;92(1):1-2.
5. Papadopoulos M, Cable N, Rahi J, Khaw PT. The British Infantile and Childhood Glaucoma (BIG) Eye Study. *Invest Ophthalmol Vis Sci* 2007;48(9):4100-6.
6. Meyer G, Schwenn O, Grehn F. [Trabeculotomy in congenital glaucoma: comparison to goniotomy]. *Ophthalmologie* 2000;97(9):623-8.
7. Meyer G, Schwenn O, Pfeiffer N, Grehn F. Trabeculotomy in congenital glaucoma. *Graefes Arch Clin Exp Ophthalmol* 2000;238(3):207-13.
8. Mendicino ME, Lynch MG, Drack A, et al. Long-term surgical and visual outcomes in primary congenital glaucoma: 360 degrees trabeculotomy versus goniotomy. *J AAPOS* 2000;4(4):205-10.
9. Beck AD, Lynch MG. 360 degrees trabeculotomy for primary congenital glaucoma. *Arch Ophthalmol* 1995;113(9):1200-2.
10. Beck AD, Lynn MJ, Crandall J, Mobin-Uddin O. Surgical outcomes with 360-degree suture trabeculotomy in poor-prognosis primary congenital glaucoma and glaucoma associated with congenital anomalies or cataract surgery. *J AAPOS* 2011;15(1):54-8.
11. Girkin CA, Rhodes L, McGwin G, et al. Goniotomy versus circumferential trabeculotomy with an illuminated microcatheter in congenital glaucoma. *J AAPOS* 2012;16(5):424-7.
12. Rabiah PK. Frequency and predictors of glaucoma after pediatric cataract surgery. *Am J Ophthalmol* 2004;137(1):30-7.
13. Swamy BN, Billson F, Martin F, et al. Secondary glaucoma after paediatric cataract surgery. *Br J Ophthalmol* 2007;91(12):1627-30.
14. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. *Am J Epidemiol* 1991;134(10):1102-10.
15. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. *Ophthalmology* 1992;99(10):1499-504.
16. Dielemans I, Vingering JR, Wolfs RC, et al. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. *Ophthalmology* 1994;101(11):1851-5.
17. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. *Ophthalmology* 1996;103(10):1661-9.
18. Leske VC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. *Arch Ophthalmol* 1994;112(6):821-9.
19. Weih LM, Nanjian M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. *Ophthalmology* 2001;108(11):1966-72.
20. Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. *Arch Ophthalmol* 2001;119(12):1819-26.
21. Dandona L, Dandona R, Srinivas M, et al. Open-angle glaucoma in an urban

Classification and Terminology

- population in Southern India: the Andhra Pradesh eye disease study. *Ophthalmology* 2000;107(9):1702-9.
22. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. *Ophthalmology* 2004;111(9):1641-8.
 23. Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. *Ophthalmology* 2004;111(8):1439-48.
 24. Topouzis F, Wilson MR, Harris A, et al. Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. *Am J Ophthalmol* 2007;144(4):511-9.
 25. Shen SY, Wong TY, Foster PJ, et al. The prevalence and types of glaucoma in Malay people: the Singapore Malay eye study. *Invest Ophthalmol Vis Sci* 2008;49(9):3846-51.
 26. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. *Surv Ophthalmol* 2008;53 Suppl1:S3-10.
 27. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. *Invest Ophthalmol Vis Sci* 2003;44(9):3783-9.
 28. Czudowska MA, Ramdas WD, Wolfs RC, et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. *Ophthalmology* 2010;117(9):1705-12.
 29. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. *Ophthalmology* 2008;115(1):85-93.
 30. Jiang X, Varma R, Wu S, et al. Baseline risk factors that predict the development of open-angle glaucoma in a population: the Los Angeles Latino Eye Study. *Ophthalmology* 2012;119(11):2245-53.
 31. Leske MC, Connell AM, Wu SY, et al. Risk factors for open-angle glaucoma. The Barbados Eye Study. *Arch Ophthalmol* 1995;113(7):918-24.
 32. Nemesure B, Honkanen R, Hennis A, et al. Incident open-angle glaucoma and intraocular pressure. *Ophthalmology* 2007;114(10):1810-5.
 33. Mason RP, Kosoko O, Wilson MR, et al. National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies. Part I. Prevalence findings. *Ophthalmology* 1989;96(9):1363-8.
 34. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA* 1991;266(3):369-74.
 35. Varma R, Wang D, Wu C, et al. Four-year incidence of open-angle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study. *Am J Ophthalmol* 2012;154(2):315-25 et1.
 36. Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. *Arch Ophthalmol* 1998;116(12):1640-5.
 37. Leske MC, Nemesure B, He Q, et al. Patterns of open-angle glaucoma in the Barbados Family Study. *Ophthalmology* 2001;108(6):1015-22.
 38. McCarty CA, Taylor HR. Pseudoexfoliation syndrome in Australian adults. *Am J Ophthalmol* 2000;129(5):629-33.
 39. Mitchell P, Wang JJ, Hourihan F. The relationship between glaucoma and pseudoexfoliation: the Blue Mountains Eye Study. *Arch Ophthalmol* 1999;117(10):1319-24.
 40. Astrom S, Lindén C. Incidence and prevalence of pseudoexfoliation and open-angle glaucoma in Northern Sweden: I. Baseline report. *Acta Ophthalmol Scand* 2007;85(8):828-31.
 41. Hirvela H, Luukinen H, Laatikainen L. Prevalence and risk factors of lens opacities in the elderly in Finland. A population-based study. *Ophthalmology* 1995;102(1):108-17.
 42. Arvind H, Raju P, Paul PG, et al. Pseudoexfoliation in South India. *Br J Ophthalmol* 2003;87(11):1321-3.

Classification and Terminology

43. Arnarsson A, Damij KF, Sverrisson T, et al. Pseudoexfoliation in the Reykjavik Eye Study: prevalence and related ophthalmological variables. *Acta Ophthalmol Scand* 2007;85(8):822-7.
44. Krishnadas R, Nirmalan PK, Ramakrishnan R, et al. Pseudoexfoliation in a rural population of Southern India: the Aravind Comprehensive Eye Survey. *Am J Ophthalmol* 2003;135(6):830-7.
45. Thomas R, Nirmalan PK, Krishnaiah S. Pseudoexfoliation in Southern India: the Andhra Pradesh Eye Disease Study. *Invest Ophthalmol Vis Sci* 2005;46(4):1170-6.
46. Ringvold A, Blika S, Elsas T, et al. The middle-Norway eye-screening study. II. Prevalence of simple and capsular glaucoma. *Acta Ophthalmol (Copenh)* 1991;69(3):273-80.
47. Topouzis F, Wilson MR, Harris A, et al. Risk factors for primary open-angle glaucoma and pseudoexfoliative glaucoma in the Thessaloniki eye study. *Am J Ophthalmol* 2011;152(2):219-28 et.
48. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol* 2002;120(6):714-20; discussion 329-30.
49. Mitchell P, Hourihan F, Sandbach J, Wang JJ. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. *Ophthalmology* 1999;106(10):2010-5.
50. Attebo K, vers RQ, Mitchell P. Refractive errors in an older population: the Blue Mountains Eye Study. *Ophthalmology* 1999;106(6):1066-72.
51. Kuzin AA, Varma R, Reddy HS, et al. Ocular biometry and open-angle glaucoma: the Los Angeles Latino Eye Study. *Ophthalmology* 2010;117(9):1713-9.
52. Xu L, Wang Y, Wang S, Jonas JB. High myopia and glaucoma susceptibility the Beijing Eye Study. *Ophthalmology* 2007;114(2):216-20.
53. Grodum K, Heiji A, Bengtsson B. Refractive error and glaucoma. *Acta Ophthalmol Scand* 2001;79(6):560-6.
54. Wong TY, Klein BE, Klein R, et al. Refractive errors, intraocular pressure, and glaucoma in a white population. *Ophthalmology* 2003;110(1):211-7.
55. Perera SA, Wong TY, Tay WT, et al. Refractive error, axial dimensions, and primary open-angle glaucoma: the Singapore Malay Eye Study. *Arch Ophthalmol* 2010;128(7):900-5.
56. Hulsman CA, Vingerling JR, Hofman A, et al. Blood pressure, arterial stiffness, and open-angle glaucoma: the Rotterdam study. *Arch Ophthalmol* 2007;125(6):805-12.
57. Bonomi L, Marchini G, Marraffa M, et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. *Ophthalmology* 2000;107(7):1287-93.
58. Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. *Arch Ophthalmol* 1995;113(2):216-21.
59. Memarzadeh F, Ying-Lai M, Chung J, et al. Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci* 2010;51(6):2872-7.
60. Zheng Y, Wong TY, Mitchell P, et al. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the singapore malay eye study. *Invest Ophthalmol Vis Sci* 2010;51(7):3399-404.
61. Topouzis F, Wilson MR, Harris A, et al. Association of open-angle glaucoma with perfusion pressure status in the Thessaloniki Eye Study. *Am J Ophthalmol* 2013;155(5):843-51.
62. Gherghel D, Orgul S, Guglietta K, et al. Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage. *Am J Ophthalmol* 2000;130(5):597-605.

Classification and Terminology

63. Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma. *Prog Retin Eye Res* 2002;21(4):359-93.
64. Grieshaber MC, Mozafarneh M, Flammer J. What is the link between vascular dysregulation and glaucoma? *Surv Ophthalmol* 2007;52 Suppl 2:S144-54.
65. Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. *Curr Opin Ophthalmol* 1996;7(2):93-8.
66. Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. *Arch Ophthalmol* 2002;120(7):954-9.
67. Topouzis F, Founti P. Weighing in ocular perfusion pressure in managing glaucoma. *Open Ophthalmol J* 2009;3:43-5.
68. Caprioli J, Coleman AL. Blood pressure, perfusion pressure, and glaucoma. *Am J Ophthalmol* 2010;149(6):704-12.
69. Khawaja AP, Crabb DP, Jansonius NM. The role of ocular perfusion pressure in glaucoma cannot be studied with multivariable regression analysis applied to surrogates. *Invest Ophthalmol Vis Sci* 2013;54(7):4619-20.
70. Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European Glaucoma Prevention Study. *Ophthalmology* 2005;112(3):366-75.
71. Gordon MO, Torri V, Miglior S, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. *Ophthalmology* 2007;114(1):10-9.
72. Leske MC, Heiji A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. *Ophthalmology* 2007;114(11):1965-72.
73. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. *Ophthalmology* 2004;111(9):1627-35.
74. Musch DC, Gillespie BW, Lichter PR, et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study: the impact of treatment and other baseline factors. *Ophthalmology* 2009;116(2):200-7.
75. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. *Am J Ophthalmol* 1998;126(4):498-505.
76. Heiji A, Bengtsson B, Hyman L, Leske MC. Natural history of open-angle glaucoma. *Ophthalmology* 2009;116(12):2271-6.
77. Leske MC, Heiji A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. *Arch Ophthalmol* 2003;121(1):48-56.
78. Bengtsson B, Leske MC, Hyman L, Heiji A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. *Ophthalmology* 2007;114(2):205-9.
79. Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. *Ophthalmology* 2008;115(7):1123-9 e3.
80. Bengtsson B, Heiji A. Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field loss in high-risk ocular hypertension. *Graefes Arch Clin Exp Ophthalmol* 2005;243(6):513-8.
81. Bengtsson B, Leske MC, Yang Z, Heiji A. Disc hemorrhages and treatment in the early manifest glaucoma trial. *Ophthalmology* 2008;115(11):2044-8.
82. Hollands H, Johnson D, Hollands S, et al. Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review. *JAMA* 2013;309(19):2035-42.

Classification and Terminology

83. Miglior S, Torri V, Zeyen T, et al. Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. *Am J Ophthalmol* 2007;144(2):266-75.
84. Kim SH, Park KH. The relationship between recurrent optic disc hemorrhage and glaucoma progression. *Ophthalmology* 2006;113(4):598-602.
85. Ritch R, Schlotzer-Schrehardt U, Konstas AG. Why is glaucoma associated with exfoliation syndrome? *Prog Retin Eye Res* 2003;22(3):253-75.
86. Holló G, Konstas AGP. Exfoliation syndrome and exfoliative glaucoma, 2nd ed. Savona (IT): Publicomm S.r.l., 2012.
87. Topouzis F, Coleman AL, Harris A, et al. Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. *Am J Ophthalmol* 2008;145(2):327-35.
88. Visontai Z, Merrisch B, Kollai M, Hollo G. Increase of carotid artery stiffness and decrease of baroreflex sensitivity in exfoliation syndrome and glaucoma. *Br J Ophthalmol* 2006;90(5):563-7.
89. Anastasopoulos E, Topouzis F, Wilson MR, et al. Characteristics of pseudoexfoliation in the Thessaloniki Eye Study. *J Glaucoma* 2011;20(3):160-6.
90. French DD, Margo CE, Harman LE. Ocular pseudoexfoliation and cardiovascular disease: a national cross-section comparison study. *N Am J Med Sci* 2012;4(10):468-73.
91. Tarkkanen A, Reunanen A, Kivela T. Frequency of systemic vascular diseases in patients with primary open-angle glaucoma and exfoliation glaucoma. *Acta Ophthalmol* 2008;86(6):598-602.
92. Traverso CE, Spaeth GL, Starita RJ, et al. Factors affecting the results of argon laser trabeculoplasty in open-angle glaucoma. *Ophthalmic Surg* 1986;17(9):554-9.
93. Armarsson A, Sasaki H, Jonasson F. Twelve-year incidence of Exfoliation Syndrome in the Reykjavik Eye Study. *Acta Ophthalmol* 2013;91(2):157-62.
94. Gottanka J, Johnson DH, Grehn F, Lutjen-Drecoll E. Histologic findings in pigment dispersion syndrome and pigmentary glaucoma. *J Glaucoma* 2006;15(2):142-51.
95. Carassa RG, Bettin P, Fiori M, Brancato R. Nd:YAG laser iridotomy in pigment dispersion syndrome: an ultrasound biomicroscopic study. *Br J Ophthalmol* 1998;82(2):150-3.
96. Liu L, Ong EL, Crowston J. The concave iris in pigment dispersion syndrome. *Ophthalmology* 2011;118(1):66-70.
97. Yang JW, Sakiyalak D, Krupin T. Pigmentary glaucoma. *J Glaucoma* 2001;10(5 Suppl 1):S30-2.
98. Siddiqui Y, Ten Hulzen RD, Cameron JD, et al. What is the risk of developing pigmentary glaucoma from pigment dispersion syndrome? *Am J Ophthalmol* 2003;135(6):794-9.
99. Niyadurupola N, Broadway DC. Pigment dispersion syndrome and pigmentary glaucoma - a major review. *Clin Experiment Ophthalmol* 2008;36(9):868-82.
100. Ayala M. Long-term Outcomes of Selective Laser Trabeculoplasty (SLT) Treatment in Pigmentary Glaucoma Patients. *J Glaucoma* 2013.
101. Reistad CE, Shields MB, Campbell DG, et al. The influence of peripheral iridotomy on the intraocular pressure course in patients with pigmentary glaucoma. *J Glaucoma* 2005;14(4):255-9.
102. Suner I, Greenfield DS, Miller MP, et al. Hypotony maculopathy after filtering surgery with mitomycin C. Incidence and treatment. *Ophthalmology* 1997;104(2):207-14; discussion 14-5.
103. Jensen PK, Nissen O, Kessing SV. Exercise and reversed pupillary block in pigmentary glaucoma. *Am J Ophthalmol* 1995;120(1):110-2.

Classification and Terminology

104. Papaconstantinou D, Georgalas I, Kourti N, et al. Lens-induced glaucoma in the elderly. *Clin Interv Aging* 2009;4:331-6.
105. Shota R, Kumar S, Gupta V, et al. Early predictors of traumatic glaucoma after closed globe injury: trabecular pigmentation, widened angle recess, and higher baseline intraocular pressure. *Arch Ophthalmol* 2008;126(7):921-6.
106. Rahmani B, Jahadi HR. Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. *Ophthalmology* 1999;106(2):375-9.
107. Gharaibeh A, Savage HI, Scherer RW, et al. Medical interventions for traumatic hyphema. *Cochrane Database Syst Rev* 2011(1):CD005431.
108. Siddique SS, Suelves AM, Baheti U, Foster CS. Glaucoma and uveitis. *Surv Ophthalmol* 2013;58(1):1-10.
109. Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. *Semin Ophthalmol* 2011;26(4-5):285-9.
110. Dupas B, Fardeau C, Cassoux N, et al. Deep sclerectomy and trabeculectomy in uveitic glaucoma. *Eye (Lond)* 2010;24(2):310-4.
111. Iwao K, Inatani M, Seto T, et al. Long-term Outcomes and Prognostic Factors for Trabeculectomy With Mitomycin C in Eyes With Uveitic Glaucoma: A Retrospective Cohort Study. *J Glaucoma* 2012.
112. Radcliffe NM, Finger PT. Eye cancer related glaucoma: current concepts. *Surv Ophthalmol* 2009;54(1):47-73.
113. Gedde SJ. Management of glaucoma after retinal detachment surgery. *Curr Opin Ophthalmol* 2002;13(2):103-9.
114. Bai HQ, Yao L, Wang DB, et al. Causes and treatments of traumatic secondary glaucoma. *Eur J Ophthalmol* 2009;19(2):201-6.
115. Detry-Morel M, Escarmelle A, Hermans I. Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide. *Bull Soc Belge Ophthalmol* 2004(292):45-51.
116. Jones R, 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. *Curr Opin Ophthalmol* 2006;17(2):163-7.
117. Mangouritsas G, Mourtzoukos S, Portaliou DM, et al. Glaucoma associated with the management of rhegmatogenous retinal detachment. *Clin Ophthalmol* 2013;7:727-34.
118. Lalezary M, Kim SJ, Jiramongkolchai K, et al. Long-term trends in intraocular pressure after pars plana vitrectomy. *Retina* 2011;31(4):679-85.
119. Ichhpujani P, Jindal A, Jay Katz L. Silicone oil induced glaucoma: a review. *Graefes Arch Clin Exp Ophthalmol* 2009;247(12):1585-93.
120. Nassr MA, Morris CL, Netland PA, Karcioğlu ZA. Intraocular pressure change in orbital disease. *Surv Ophthalmol* 2009;54(5):519-44.
121. Liebmann JMR, R. Complications of glaucoma surgery. In: Mosby SL, ed. *Ritch R, Shields MB, Krupin T The Glaucomas* 1986.
122. Simmons RJM, F.A. Malignant Glaucoma. In: Mosby SL, ed. *Ritch, R Shields, MB Krupin, T: The Glaucomas* 1996.
123. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. *Br J Ophthalmol* 2002;86(2):238-42.
124. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? *Br J Ophthalmol* 2001;85(11):1277-82.
125. Congdon N, Wang F, Tielsch JM. Issues in the epidemiology and population-based screening of primary angle-closure glaucoma. *Surv Ophthalmol* 1992;36(6):411-23.
126. Day AC, Baio G, Gazzard G, et al. The prevalence of primary angle closure

Classification and Terminology

- glaucoma in European derived populations: a systematic review. *Br J Ophthalmol* 2012;96(9):1162-7.
127. De Silva DJ, Gazzard G, Foster P. Laser iridotomy in dark irides. *Br J Ophthalmol* 2007;91(2):222-5.
128. Foster PJ, Aung T, Nolan WP, et al. Defining "occludable" angles in population surveys: drainage angle width, peripheral anterior synechiae, and glaucomatous optic neuropathy in East Asian people. *Br J Ophthalmol* 2004;88(4):486-90.
129. Becker B, Shaifer RN. *Diagnosis and therapy of the glaucomas*. St. Louis: C. V. Mosby Co., 1961; 360 p.
130. Friedman DSW, R. N. Consensus on Angle-closure and Angle-closure Glaucoma. AIGS/WGA Consensus Series 2008.
131. Salmon JF. Long-Term Intraocular Pressure Control After Nd:YAG Laser Iridotomy in Chronic Angle-Closure Glaucoma. *J Glaucoma* 1993;2(4):291-6.
132. Mapstone R. Provocative tests in closed-angle glaucoma. *Br J Ophthalmol* 1976;60(2):115-9.
133. He M, Friedman DS, Ge J, et al. Laser peripheral iridotomy in eyes with narrow drainage angles: ultrasound biomicroscopy outcomes. *The Liwan Eye Study. Ophthalmology* 2007;114(8):1513-9.
134. Ritch R. Plateau Iris Is Caused by Abnormally Positioned Ciliary Processes. *J Glaucoma* 1992;1(1):23-6.
135. Wand M, Grant WM, Simmons RJ, Hutchinson BT. Plateau iris syndrome. *Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol* 1977;83(1):122-30.
136. Lowe RF. Primary Angle-Closure Glaucoma. Family Histories and Anterior Chamber Depths. *Br J Ophthalmol* 1964;48:191-5.
137. Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. *Curr Opin Ophthalmol* 2007;18(2):129-33.
138. Tanihara H, Nishiwaki K, Nagata M. Surgical results and complications of goniosynechialysis. *Graefes Arch Clin Exp Ophthalmol* 1992;230(4):309-13.
139. Lam DS, Chua JK, Tham CC, Lai JS. Efficacy and safety of immediate anterior chamber paracentesis in the treatment of acute primary angle-closure glaucoma: a pilot study. *Ophthalmology* 2002;109(1):64-70.
140. Lai JS, Tham CC, Chua JK, et al. To compare argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure: mid-term results. *Eye (Lond)* 2006;20(3):309-14.
141. Ritch R, Tham CC, Lam DS. Argon laser peripheral iridoplasty (ALPI): an update. *Surv Ophthalmol* 2007;52(3):279-88.
142. Arnavielle S, Creuzot-Garcher C, Bron AM. Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. *Graefes Arch Clin Exp Ophthalmol* 2007;245(3):345-50.
143. Greve EL. Primary angle closure glaucoma: extracapsular cataract extraction or filtering procedure? *Int Ophthalmol* 1988;12(3):157-62.
144. Tarongoy P, Ho CL, Walton DS. Angle-closure glaucoma: the role of the lens in the pathogenesis, prevention, and treatment. *Surv Ophthalmol* 2009;54(2):211-25.
145. Lai JS, Tham CC, Chan JC. The clinical outcomes of cataract extraction by phacoemulsification in eyes with primary angle-closure glaucoma (PACG) and co-existing cataract: a prospective case series. *J Glaucoma* 2006;15(1):47-52.
146. Husain R, Gazzard G, Aung T, et al. Initial management of acute primary angle closure:

Classification and Terminology

- a randomized trial comparing phacoemulsification with laser peripheral iridotomy. *Ophthalmology* 2012;119(11):2274-81.
147. Azuara-Blanco A, Burr JM, Cochran C, et al. The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle-closure glaucoma (EAGLE): study protocol for a randomized controlled trial. *Trials* 2011;12:133.
 148. Tham CC, Kwong YY, Leung DY, et al. Phacoemulsification vs phacotrabeculectomy in chronic angle-closure glaucoma with cataract: complications [corrected]. *Arch Ophthalmol* 2010;128(3):303-11.
 149. Fitch R, Tham CC, Lam DS. Long-term success of argon laser peripheral iridoplasty in the management of plateau iris syndrome. *Ophthalmology* 2004;111(1):104-8.
 150. Traverso CE, Tomey KF, Gandolfo E. The glaucomas in pseudophakia. *Curr Opin Ophthalmol* 1996;7(2):65-71.
 151. Nash RW, Lindquist TD. Bilateral angle-closure glaucoma associated with uveal effusion: presenting sign of HIV infection. *Surv Ophthalmol* 1992;36(4):255-8.
 152. Moororthy RS, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. *Surv Ophthalmol* 1997;41(5):361-94.